Quick note. I am giving the simple version of how the eye works for this essay.

There are about 126 million light-detecting cells in each eye. About 1.2 million nerve fibers carry signals from each eye to the brain.

Here is the cool part. Each of those light cells, the rods and the cones, has a tip that does the actual catching. And that tip is built to be thrown away. Catching light literally breaks the molecules that do the catching (rhodopsin in the rods). And it is catching all day. Every one of those millions of cells, breaking and remaking those molecules, more times than anyone could ever count. Think the atoms in a room. That is how much work your eyes do without you ever feeling it.

So the tip is disposable. Every rod throws away its whole tip and grows a new one about every ten days, your whole life. One of the fastest rebuild jobs in the body. Think brake pads. You do not replace the car. You replace the part that wears.

Okay. Now here is what matters for us. The making of new tips is not the part that breaks. The cell keeps trying to rebuild. What breaks is the upkeep. Every rebuild ships its parts down one narrow neck (the connecting cilium) to reach the tip, and that neck needs a crew of proteins to keep it clean and moving.

In many forms of USH and RP, that crew is the broken part. And it goes back to our genes. A gene is the recipe for a protein. The gene for that crew has an error in ours. So the crew comes out broken, or never gets built at all. There is even a name for this whole family of disease. A ciliopathy. A disease of that one narrow neck.

For a while the cell still keeps up. Then, as we age, the crew falls further behind. The rebuild cannot keep the connection alive. That is when the cell goes dark and dies off. Slowly, over years. That is the real reason we lose our sight. That is the root of it. How it spreads from the sides inward, and why light makes it worse, is another essay.

Okay. Back to the machine while it still works. Here is the wild part. Your eyes and your brain split the work. They split it differently between your center and your side. The center cells send their signal up almost as-is, one cell to one nerve. The side cells get bundled and pre-processed first, many cells to one nerve. Two different ways to the brain. I did not know this either. The eye feeds many of those side cells into fewer output cells (ganglion cells) that work like coprocessors. Each one does a few basic tasks. Detect motion. Detect an outline. Detect a light change.

You have over a million of these coprocessors running at the same time. Like the heart, they just keep running. They are always sending little signals. The motion-detecting ones (M-cells) fire mostly when something changes. Your brain is mostly being told when something new happens. Then it decides what to do about it.

Side vision is about twice as fast at catching motion, especially in low light. That is why side catches a thing first, then your center swings over to look.

All this pre-processing happens across 95% of your view. The other 5% is your center, where the brain does the work instead.

And the side barely does color. The color cells sit in the center. So the side hands you shape and motion, and the center fills in the detail and the color.

Your side vision sends those basic signals up. Your brain matches them to patterns you have seen before. Once the brain knows what it is seeing, it stops looking closely and just watches to see if it moves. The rest of what you “see” is your brain remembering objects you have seen.

Here is something you can try right now. Close your left eye. With your right eye, stare at one spot in front of you and hold it there. Now hold your right thumb up at arm’s length and slide it slowly out to the right, toward your ear, keeping your eye locked on that spot. Somewhere out to the side your thumbnail vanishes. Gone. And you do not see a hole. Your brain paints the background right over it. Move a little more and it comes back.

That gap is your blind spot. Every eye has one, right where the nerve leaves the back of the eye. No sensors there, so there is a real hole in everything you see. You never notice, because your brain fills it in every second by guessing from what is around it.

And here is the part most people get wrong about going blind. That missing piece did not go black. You did not see a dark dot where your thumb was. You saw the wall, filled right in. You would swear you saw it all, nothing missing. Losing your sight is not a black screen dropping down. It is your brain quietly guessing to cover a hole you cannot see.

An octopus does not have this. Its eye is wired the other way, sensors facing the light and wiring behind, so it has no hole. Ours is wired backwards, and the brain hides that from you your whole life.

We like to think we are the top species. The octopus quietly got this one right. No hole. Cleaner wiring. Humbling.

But here is the twist. Some scientists say our backwards way is not a flaw at all. With the wiring in front, the cleanup crew sits right behind the tips. Right where it needs to be to feed them and swap them every ten days. So maybe backwards was the smart bet after all. Nobody fully agrees yet. I just had to share it. And hey, if we come back, maybe I get to be an octopus next time. Then I can finally tell you if their eyes really are better.

Here is the part for us. That little hole does the same job my whole eye is doing now. Filling in what it cannot see by guessing from the edges. RP just grows the hole.

You needed a finger to even find your blind spot. Mine grew until it swallowed the trick. That spot where your thumb vanished sits out in the side vision a lot of us have already lost. So if you have RP and the demo did nothing, you did not do it wrong. That is just the hole, bigger now.

I am sharing all this for a reason. All those coprocessors sit out on the side, and they run on the side light cells. The ones we lose first. As those cells die off, the pre-processing dies with them. The side goes quiet. What is left is the center, now doing the rough side-work it was never built for, on top of its own.

That is the hardware. The side did the fast, free work, and we are losing it. In The Brain Tax I walk through what that costs us when it goes.

Mark G. Hubers

Just an Engineer with USH

Part of the cabinet series, on how Usher syndrome and RP actually work.

Read the whole series here: ushengineer.substack.com/s/essays

I study my own mind: what it used to do for free, and what it tries to do now. I have done this my whole life. It is just how I am built. There is a word for it. Metacognition. Thinking about your own thinking. It means watching the layers running at once. What the eyes saw. What the ears heard. What the brain did. What has gone wrong and what has worked. The gap between what I saw and what was really there.

The brain was built to depend on all our senses working fully. Ours are fading. It tries to use other parts that were never made for this job. It wants the old way back. It fights every step to recreate what it once had. At times it fails. At times it seems to find a new way.

We have all heard it. “Why is it so hard for you to just remember where you put it?” Like we forgot. Like we are lazy.

I had the other way once. I used to walk into a room and just know where everything was, like anyone. I am not describing something I never had. I had it, watched it go, and had to rebuild it piece by piece. You understand a thing best as you lose it.

So let me show you the engineering of what we are losing. Your brain already stores what a cup, a chair, a door look like, as rough outlines. In a sighted person, the peripheral vision catches those outlines and builds a map of the whole room from them, in milliseconds. It is not searching. It is recognizing. Researchers call this scene gist recognition. Studies show it happens in as little as 20 milliseconds.

The rough system is fast BECAUSE it is rough. It does not need detail. It just needs outlines.

Then your central vision fills in the details only where it needs to. You glance at the cup to see if it is full. You look at the door to see if it is open. But your peripheral already told you where everything was. That is why you can find a coffee cup on a messy counter so fast. Your brain remembers roughly where you set it down. Your peripheral narrows it to a zone. Your eyes jump there. Then your center vision locks on the exact spot. You still have to look. But you already have a ballpark before you start. Memory, peripheral, and center vision all feed each other.

All of that happens without you knowing. It barely taxes the brain. More recognition than thought.

For us, that part is gone. Everything we do, we think it out now. Every step. Every move. Every cup we set down.

There are two ways a brain does this work, and they have names. The fast, free one that recognizes, and the slow one that reasons it out. Scientists call them fast and slow thinking, or System 1 and System 2. Seeing where things are used to run for free on the fast one. Now we reason out every bit of it on the slow one. That swap, free recognition traded for slow reasoning, is the whole tax.

It is like doing math homework all day. Every day.

With our peripheral gone, memory and center vision are what’s left. Both overloaded. Both doing work they were never built for. Memory was never built to run the whole show. Most people hold about four things in mind at once. I hold maybe two or three. And a brain that never stops thinking drops it to one. Now it has to hold everything peripheral used to track for free. Center vision was built for detail, not scanning. Now it has to do both. Our brains were never built to run either system this hard.

Over time, it does try to remap. It shifts some of what it lost into the areas that still work. But that takes years, it never fully covers the gap, and the overload does not go away. We are running a system past what it was designed for.

You have probably heard: when you lose one sense, the others get stronger. Blind people often gain sharper hearing. Deaf people often gain sharper peripheral vision. That is partly true. But with both senses going, there are fewer good places for the rewiring to land. So the brain picks smell. It strengthens, but it does not help me find a doorway. The brain tried to compensate with what little it had left. And the smells it does sharpen? Mostly the ones I would rather smell less of.

Now for some good news. We do see details. Not because we see better. Because we have to slow down and look at each thing instead of skim past it. You know the old saying about taking time to notice the little things in life? Well, we really do. The forced version. You gotta laugh.

Center vision is slower. No shortcuts. Lock. Study. Next.

Two people walk into an office. Neither has been there. Find the clock and remember where it is. The sighted person finds it in a blink. Peripheral catches the shape, eyes snap. Those of us with USH or RP have to look at each thing. Lock, study, next. Until we land on the clock.

Now: do not look back. What color was it? What time was it? The sighted person often cannot answer. We often can. They never studied it. The color and time came along for the ride. We had to study to know it was a clock.

The big stuff still gets us. The small stuff has nowhere to hide.

Real life is harder, though. Drop us somewhere new and the whole thing falls apart. We try to scan fast. But that is not scanning. Different panics hit at the same time and the mix keeps shifting. Pressure to keep moving. Worry about looking like an idiot. The looking load itself. Pick which one.

And underneath, the looking never stops. Floor. Trails. What to stay away from. Where the bathroom is for later. All of it racing.

For many of us, all we have left is center vision. For some, even that is fading or turning blurry. And center vision, whatever is left of it, was never built for this job. It was designed for detail. High resolution, full color, fine work. It was meant to zoom in AFTER the rough map told it where to look. We are forcing it to do everything. Looking, searching, mapping, AND detail. All at once. And because it sees so much detail in every tiny area, it actually takes MORE time to process.

We are using a microscope to scan a room. That is why it is so slow and tiring. We are running the wrong tool for the job because it is the only one we have left.

If you have ever worn simulation glasses at a vision event, the ones with the tiny hole, you noticed how small the view was. But did you notice how slow you got? Your center vision was now forced to be a scanner it was never built for. You were not just looking anymore. You were thinking, and every glance became a decision. That is what we do all day. Left to right, row by row. Many of us use a finger to guide our eyes because without a reference point, the eyes drift and we lose our place.

What we do is what researchers call serial visual search. It is 5 to 30 times slower than what your peripheral does. Our visual system lost its recognition engine, forcing everything through a single, overworked core.

The mind does not just miss things. It fights to make something out of what it has. You can feel it trying. It wants to turn a partial shape into a pattern so badly that it will guess wrong. A dried leaf on the floor becomes a dead bird for a second. A sweatshirt on a chair becomes the cat. Your eyes start moving, trying to get more data. When it gets it wrong, it really gets it wrong. Like your brain hit a wall it did not expect.

Then the second hit. Did I just see a dead bird in my house? You can still see it for a beat after you know it was a leaf. How can it be that wrong? You wonder if you are hallucinating. You are not. The brain just locked onto a pattern with too little data and picked the wrong thing. You end up with this weird feeling. How dumb was I? You are OK. It happens.

Researchers call this predictive coding. Weak signal, strong guess. Ours: very weak or no signal. Bad guess. I have a name for it. Fragment-forcing. How often varies. Rare for me. More for some.

Charles Bonnet syndrome is a different thing. Mine starts with something real in the room that my brain reads wrong. Charles Bonnet starts with nothing in the room at all. The brain, starved of sight, makes a picture out of thin air. Both are a brain doing its best with broken inputs. So mine is a close cousin of Charles Bonnet, but from a different cause: too little information instead of none.

That one difference is good news. You cannot fix a picture of nothing by looking harder. You can fix a misread leaf. Because mine starts with something real, I can feed my brain more of what it is missing. Add light. Look again from a new angle. Point a finger right at the thing, because my finger sits at a known distance, and that hands my brain back the size it lost. The wrong guess falls away. It was just a brain in a hurry, working with half the picture.

And this part is hard to say out loud. Many of us keep it to ourselves because it sounds crazy. The ones who do speak up sometimes get told nothing is wrong. But it is real. It has a name. We are not making it up.

One more thing while we are at it. When your center view needs to move, it does not really move. It jumps.

Your eyes jump hundreds of times per minute. Each one less than a quarter of a second. During each jump, your brain pauses your vision so you do not see a blur. Same reason a moving camera takes a blurry photo.

When your eyes jump, the brain normally uses your side vision as the anchor for where things are. The center is blanked the most during that pause. The side keeps more of its motion signal. The brain stitches the two views together so the world feels continuous.

We have lost most of that anchor. The side view is gone or fading. So during every eye jump, our brain has nothing to hold position with. That is why scanning is hard.

Reading word to word goes fine. Short jumps. End of the line is where it breaks. We have to make a long jump back to the start of the next line. Far enough that we sometimes land on the wrong line, off by one up or down. We catch ourselves asking: did I just read this line, or did I miss one?

Searching for something on the table or the floor, our eyes float in every direction. We can be looking right next to the object and still feel like it is worlds away. We cannot scan in a straight line, no matter how hard we try. The jump costs us our reference. We have to land, lock, then move again. One step of search at a time.

On a computer I put my mouse pointer at the start of the line I am about to read. That gives me an anchor. On a Kindle the pointer trick does not work, so I set the line spacing wider instead. Same idea. Give my eyes a bigger target to land on.

This is why it feels like war to us. We lost the hardware that did the job. Other hardware has to fill in. I have to be my own pattern-detection algorithm, because the one in my eyes has crashed. That is the cost of a 5-degree visual field.

USH and RP folks reading this. We are not going crazy. The brain is just running short of real input from our eyes. This is normal for what we have.

And there is another part people miss about losing sight. It is not just less light. It is shape and color and shadow, all cut down. We see less inside shadows, and we see the shadows themselves less.

That is a bigger deal than most know. The brain uses many cues to build the 3D world. Shadows. Motion in your side view. Stereo vision from both eyes overlapping. Many others. We lose most of these at once.

That is why steps look flat. Why we trip in broad daylight when light is fine. Why we can read a book just fine, then bump into a wall walking away from it.

None of this shows up on any test. But it is real. Our eyes used to do this work for free. Now we pay for it every waking minute. That is the brain tax.

And I still do it. Not every time. But enough. And it is not just doors. It is everything.

If you live with me, or with anyone who has Usher syndrome (USH) or retinitis pigmentosa (RP), you already know this. You have probably said something about it. Maybe you laughed. Maybe you walked into one. Maybe you gave up and just started closing them yourself. A USH friend emailed me this. Her husband once said if she keeps leaving the cabinet doors open, he is going to remove all the doors. Honestly, that might be the best idea anyone has ever had.

But here is the thing everyone asks us. Why can you not just remember to close it? I know. I know. Put the frustration down for a minute and keep reading. I promise it will make sense by the end. And if it does not, you can go back to being mad at us.

We are trying. None of it comes natural anymore. Every step of our lives has to be planned now. Where to place the cup every single time. Where to put the phone, the flashlight. How to walk through a room. Whether to hold a door open or close it now and reopen it later.

We build patterns for everything, learn what works the hard way, and try to stick to them. It is a running list of habits we train ourselves into day after day. Stick with it long enough and it becomes muscle memory. That helps. But it is always work.

And even with all that effort, we still miss things. The cabinet door is just the one everyone notices. Because the moment we open it, we cannot see it anymore.

The Geometry of Gone

For those of us who have retinitis pigmentosa (RP), which is the vision loss side of Usher syndrome (USH), our visual field is shrinking from the outside in. A healthy eye sees about 180 degrees wide. At 40 degrees, things start going wrong but we blame other stuff. At 30 degrees, you cannot deny it. Once you drop below 20 degrees, you are in the legally blind range.

How far and how fast this goes depends on your type and your genes. Mine is USH2. Hearing I manage with aids, and vision that started narrowing in my teens. USH1 folks are often born deaf, with balance off from the start. USH3 can start with more hearing and lose it over the years. And many people have RP with no hearing loss at all. Different starts. The narrowing field is the part most of us share.

Some of us notice it early. Some not for years. I am around 5 degrees now. On bad days it drops to about 2. It shifts with stress, lighting, fatigue, and a mix of other things.

What I am describing runs from about 30 degrees down to about 2 degrees. Below 2 degrees, there is not much left to work with. That is a different essay. I am not there yet. I hope I never have to write that essay. But that may be in the cards.

OK, here is what it is like for those of us at about 10 to 5 degrees. If you are standing one foot (30 cm) to my left, I do not see you. One foot to my right, I do not see you. Below my eye level, I do not see you. You are right there, close enough to touch me. But unless I move my head and eyes to find you, I do not know you are there.

And the hearing does not save us either. For most of us the hearing works somewhat. We can hear you when you talk. But the faint sounds barely register for us. A body shifting next to me. A faint breath. Footsteps on carpet. Most of you hear those without thinking. Your brain registers them. Ours never gets the signal.

Combine that with the vision gaps and we would not know if anyone walked right up to us from anywhere around. The eyes miss the sides. The ears miss the faint cues. So when both fail together, we miss everything.

Two systems are broken for the same reason. The first is the alert. Peripheral and ears fire when something enters our space. Ours do not. People walk up and we never knew they were coming.

The second is the map. Peripheral vision maps the room around us and builds a 3D world of where every wall and object is. It does this in milliseconds without us trying. Our auto sensors for this are fading or have faded away.

Most new things, or a new home for something, will just about never register until we look right at it or are told about it. Center vision can scan to find them, but scanning is slow and choppy. If we are not actively thinking about something, it might as well not exist.

Let me show you. A friend is over. We are talking, laughing, opening bottles. I put my cap down on the counter. They put theirs down right next to mine, a cap’s width away. A few minutes later I see my cap. Lucky I spotted it. Should have trashed it when I opened the bottle, knowing most times I never would have spotted it. I walk over, look down, grab what I see, throw it away. To me there was one cap. I picked it up. Done.

The second cap is still sitting there. A cap’s width from where mine was. I never knew it existed. My eye locked on the cap I was looking at, and my field does not extend past the object I am focused on. A cap’s width to the side is gone.

The friend watches this and does not know what to make of it. A minute ago I walked over without bumping anything. I spotted my own cap. I picked it up cleanly. So how did I miss theirs sitting right next to mine?

This is the part that makes it so hard to explain. Most of the time we look like we see just fine. Then we miss something right in front of us, and nobody knows what to think. Not even us. One moment we see something. The next we miss what is right there. We cannot explain that either.

To me, that cap was never there. Not forgotten. Not ignored. Not there. And I never heard it go down either. Most people pick that up without thinking. A cap hits a counter and their ear registers it for them. Mine does not. Two cues missed. Not one.

A cap’s width outside center might as well be on the moon.

Think about what happens when you open a cabinet. You reach up, grab the handle, pull it open. The door swings up or out. You look inside. You reach for what you need. You grab it. You turn away.

The door is still open. But it is no longer in front of you. It swung into the space above or beside your head. The space you cannot see. Three steps. Open, grab, close. Should be easy. Wrong.

For someone with full vision, here is what your brain does without you knowing. You open the cabinet and start to move away. The shape on the edge of your vision is wrong. Maybe danger. It forces your eyes back to check. The door is still open. The whole thing takes a fraction of a second and you did not choose to do any of it.

Your peripheral does two things you take for granted. Without thinking. First, it detects movement. Something shifted. Second, it detects when a shape does not match what the brain expects. An open door where a closed one should be. Both trigger your eyes to look. One catches change. The other catches wrong.

Here is the key to all of it. Your peripheral sees objects, identifies them in a flash, asks if they are safe, and moves on. No color. No detail. Just outline against background, and where it sits in space. You never know it is happening. It only flags you when something does not match. A basket in a walkway that was not there before.

Then it triggers what researchers call a saccade. I learned there was a word for it years after I noticed it happening. A saccade is when your eyes dart to something without you telling them to. It is a reflex. Your peripheral detects the mismatch, and your eyes jump to it automatically so your central vision can identify what it is. The same loop runs in your hearing.

For us, that system is gone. The rod cells that detect those changes are dead. No pattern shift. No saccade. No alert. Our eyes do not jump to the open door. They do not catch the bottle cap or the moved basket or the outstretched hand. Nothing in our peripheral triggers a look. So we never look. And if we never look, we never see it.

The sensor never fires. The door stays open because our brain never got the signal that it was there. My brain never updated the software. It is still waiting for an interrupt from hardware that has been disconnected. It still thinks the door is handled, so it moved on to the next thing.

You cannot close what you cannot see.

And it is rarely just three steps. Open the door, grab the cup, close the door. That sounds simple. But add in someone talking to you, or the lighting is off, or you have to feel around inside because you cannot see the shelf clearly, or you are holding something in the other hand. Now it is six or seven steps.

And here is something most people do not know. For a new task, the brain can only hold about three or four steps at once. Not ten. About four. The name for this is working memory. It holds only a short set of things at a time.

So by step four or five, the door you opened at step one is gone. Your brain dropped it to make room for the next thing. It is forgetting, but not the kind you think. The brain is forced to dump the oldest step to make room for the newest one coming in.

And if you try to hold more than that, you are not remembering anymore. You are rehearsing. Looping the steps in your head over and over. That costs even more brain power, and now you are thinking about remembering instead of doing the task.

You have felt this. Someone gives you a phone number and then starts talking. The number starts slipping because your brain cannot hold it and listen at the same time. That is how all human brains work.

Now imagine that with a cabinet door. You open it. You look for the cup on the dark shelf. You grab it. And your mind is not on any of it.

This is the part people miss. Almost anything pulls your mind off the task. Most of the time it is your own head. You are already running the day. I am still waking up. I have to feed the pet and fill the water bowl. The cup is the small thing in your hand. Your mind is on the whole day.

Or it is someone talking to you. Same result. You never think “close the door.” You are thinking about your morning, or answering them. The side vision that used to catch the open door for free is gone. And your mind, the last backup, has moved on. The few basic steps fall apart. You got sidetracked and lost the thread.

Think of how you click around the web or social media. You open one thing, jump to the next, and a minute later you forget what you came for. That is how the mind works most of the time. Now do that with a door you cannot see.

The difference is sighted people do not need to remember the door because their peripheral vision is still tracking it for free. We do not have that backup. When it drops out of memory, it is gone.

A Living Example

A hot summer night. I end the day with a quick shower, so the aids are out. Then I have to remind myself to put them back in before I brush my teeth. I learned that the hard way. With the aids out I cannot hear a running faucet, and a few times I left one going without knowing. So now they stay in until I reach my bed.

Aids in, hearing catches the running tap for me, no memory needed. Aids out, that is one more thing my memory has to track.

I open the cabinet under the sink for my electric toothbrush and water pick. The cabinet door is now open. I brush my teeth. And my brain is already gone, running the day back. Work. The house. That bill I need to pay. The same end-of-day loop everyone runs. My mind will not sit still at the sink.

I put everything back under the sink. Brain is still jumping from subject to subject. Clean teeth. Good feeling. A few minutes ago I was dreading having to brush. Now I am glad I did. Feels good every night. I bet we all feel that.

I take my first step away and wham right into the lower cabinet door I left open five minutes ago. I have almost ripped that door off three times now.

That is the whole thing in one scene. Because the moment we opened it, we never saw it being open. Nothing registered. Nothing to remember. Nothing to track.

Tom V.A., a member of our community, calls hearing “the forgotten plain Jane of Usher syndrome.” He’s right. For those new to Usher syndrome, it takes both your hearing and your vision. Most of us are also going blind. My other essays cover the vision side. This one is about the ears.

We talk about the eyes. We talk about tunnel vision, night blindness, the shrinking world. But for most of us, the hearing loss came first. It was there from day one. Everyone else focuses on the eyes. We never stopped thinking about the ears. It’s always there. Always a struggle in some way.

This essay is about what’s going on inside your ear, what’s going wrong, and what it feels like to live it. I worked with sound processing long ago, so I’ll try to explain it the way I understand it.

So let’s start with something basic. Sound and noise aren’t the same thing. Sound is what you’re trying to hear. Noise is everything else. A hearing person’s brain sorts them apart without thinking about it. Ours can’t. Everything comes in at once and competes for the same space.

If you’re hard of hearing, noise feeds on the little you have. Every fan, every TV, every voice in the background eats into the words you’re trying to catch. The hearing world tunes it out. We can’t. It stacks up until the words we need are buried.

Not just restaurants. Anywhere outside your own home. Even at home, someone has a TV on and thinks you should hear fine. You don’t. But you let a lot of it slide because you have to pick your battles.

If you’re profoundly deaf, sound is everything you’re not getting. All of it. The whole room. Not just the conversation you’re missing. The music, the laughter, the door that just closed behind you, the phone that slipped out of your pocket or off your lap and you didn’t hear it hit the floor. Most people never stop to think about what that means.

Two different kinds of loss. Both invisible. Both exhausting in their own way. And both living in the same hearing world.

I’ll say something to my deaf and hard of hearing friends that not everyone wants to hear. And if you’re hearing, stay with me. Your part is coming.

This is a two-way street. We have to accept that.

We can’t expect everyone around us to learn sign language, the same way we can’t expect everyone to learn every language on earth. You’d leave someone out no matter what.

But the people close to you, your family, your friends, the ones who matter, they should try. And to those people: face me when you talk. Get my attention first. Turn the TV down.

That’s the other side of the two-way street. We meet the world halfway, and the people who love us meet us the other half.

Learn when you need to be heard, and learn when to let it go. That’s hard to take. But that’s life.

That’s just how I see it. I don’t do this often in my essays, and I’ll try not to make a habit of it. But sometimes you have to say what you actually think.

If someone in your life has hearing loss, this is what they’re not telling you. Not because they don’t want to. Because it’s hard to put into words. That’s what I’m trying to do here.

How Hearing Actually Works

Your inner ear has a tiny spiral about the size of a pea (the cochlea). It’s filled with fluid that carries the sound in. Inside it are thousands of hair cells, and those hair cells are how you hear.

Think of them as tiny grass blades standing in rows, nice and straight when there’s no sound. Short ones, medium ones, tall ones, lined up like a staircase.

When sound enters the cochlea, it creates waves in the fluid. The waves bend the shorter hairs into the taller ones, and that triggers a switch. That switch creates the electrical signal your brain hears. There’s a lot more going on at that level (stereocilia mechanotransduction), but that’s the basic idea.

That signal travels through the hearing nerve (auditory nerve) to your brain, and your brain turns it into “I heard the word ‘hello.’”

That part is simple. Short hairs bend into the tall ones and a switch triggers. Easy enough. But my engineering brain won’t leave it alone. The tall one is bigger, so shouldn’t the waves move THAT one more? Why does the short one do the work? It doesn’t matter for this essay, but I wanted you to see how my brain works. I’m always pulling things apart, even the basic stuff. That’s just how I think.

The cochlea maps sound by location. Think of it like a piano. High notes on one end, low notes on the other. Your cochlea works the same way. Every sound you hear uses some combination of those keys.

The hair cells are connected to each other by tiny protein threads. The ones at the tips are called tip links. The ones at the base are called ankle links. When those connections are broken, the keys stop working.

Each Usher type has different connections broken. Some are missing almost all their keys from birth. Some were born without the high keys and never had them. Some start with most keys working and lose them over time.

What It’s Actually Like

This is how it works for me. If you still have some good hearing, count yourself lucky, but a lot of this will still feel familiar. For those who are profoundly deaf and losing vision, it’s different and in some ways harder. Some are reading signs by placing their hands on the signer’s hands to feel the shapes being made (tactile sign language), because they can’t see the hands or hear the voice. Some of us may end up there one day. I hope I don’t, but I can’t promise that. What I can say is there’s more hope now than ever. Gene editing, pills that slow the damage, treatments that stabilize what’s left. The science is moving. We all have our own version of this fight.

When someone says a word, that word needs certain keys to sound right. If the word uses keys you don’t have, you don’t hear silence where that sound should be. The sounds around it bleed into that space. The tone shifts.

What reaches your brain is a distorted version of the word, not a word with a hole in it. Your brain takes that mess and pattern-matches it to the closest word it knows. Sometimes it’s right. Sometimes you hear a completely different word that sounded close enough.

Say someone says “think.” The TH is on a high key I don’t have. But I don’t hear “ink.” I hear something that sounds like it could be “think” or “fink” or “sink” because the sounds next to it color what I get. My brain picks one. If the conversation is about ideas, it picks “think.” If we’re talking about a kitchen, maybe it picks “sink.” Context does the work my ears can’t.

And some sounds just disappear entirely. The S at the end of a word has nothing after it to bleed into. It’s just gone. So “cat” and “cats” sound the same to me. One or many? I have to figure that out from the rest of the sentence, if the sentence was long enough to give me a clue.

The harder ones are words that start with a sound you don’t hear. You’re already behind before the word even gets going. By the time you catch the middle, you missed the opening and your brain is guessing from half a word.

Here’s what a sentence sounds like to me versus you.

Say someone says: “She thinks the store on the corner closes at six on Thursdays, so we should probably leave before five thirty if we want to make it.” That’s a long sentence. I hear: “She think the store on the corner close at si on Thurday, so we should probably leave before five thirty if we want to make it.” The S’s are gone. Thinks becomes think. Closes becomes close. Six could sound like sit. Thursdays becomes Thurday. But I got most of it because there’s enough flow. Enough words around the missing ones to fill in what I didn’t hear. My brain adds back the S’s because it knows how sentences work.

Now say someone just says: “Six.” By itself. Did they say six? Sit? Stick? Sick? I have no idea. Same word, but with nothing around it, I can’t tell. Or “She thinks so.” Three words. Not enough to build on. Think becomes thi–, she becomes ee, so is fine. But I’m guessing at two out of three words.

The longer someone talks about the same thing, the better I follow. The shorter the sentence, the harder it is. One or two words by themselves? I might not know any of them. But even a long sentence can fall apart if I miss too many words in a row. Enough gaps and the whole thing collapses no matter how long it is.

And here’s something nobody talks about. My brain doesn’t just process forward. It goes back. Say I hear a word wrong early in a sentence. I keep listening. Five or ten words later, new context comes in and my brain goes back and replaces the wrong word with the right one.

I didn’t hear it better. My brain figured out what it had to be from what came after. Sometimes I can feel it happen. A word I thought I heard gets quietly replaced with the right one.

I’m not just listening. I’m running a prediction engine forward and a correction engine backward at the same time.

And here’s what that costs: while my brain is going back to fix the words it got wrong, I’m missing the new ones coming in. For a moment, I’m offline. Rebuilding the past and losing the present at the same time. Then I come back and have to catch up on what I missed while I was fixing what I misheard.

If you want to know what this feels like, think about learning a new language. Remember trying to follow someone speaking French or Spanish? You catch a few words, guess the rest, your brain goes back and corrects, and while it’s correcting they’ve moved on. Short sentences are harder than long ones. You’re exhausted after thirty minutes. That’s what hearing loss is. Except it’s in your own language. Not because we don’t know it. Because we can’t hear every word right. And it’s every conversation. All day. For life.

And that’s the hardest part of all. Following a conversation is like building a puzzle without the picture on the box. You start catching pieces, matching them to context, using lips and tone and what you know about the topic. After a minute or two, you’re keeping up. You’re in it.

Then someone changes the subject. That’s not rude, that’s just how people talk. One thing leads to another. Everyone wanders, the same way you wander the internet or scroll through your phone.

But for us, every topic change is a crash back to zero. All that context you built is gone. You’re starting over with no picture, no pieces, trying to figure out what they’re even talking about now. That happens over and over, all day.

So how can you help? Watch for it. If you see us go quiet or our face changes, we probably just lost the thread. Don’t keep going. Stop. Say “we just switched to talking about…” and give us the new topic. That one sentence puts us back in the game.

Ask us if we’re following. And if we ask you to repeat, please just repeat it. Don’t sigh. Don’t get frustrated. Don’t hit us with “I SAID…” We know you said it. We’re not asking to annoy you. We’re asking because we want to hear you.

And don’t say “never mind” or “I’ll tell you later.” There is NEVER a later. That moment passes and it’s gone. And every time you say it, it hurts. It was important enough to say once. Say it again. Without the sigh. Without the look on your face that tells us we’re a burden for asking.

And I haven’t even told you the worst part yet. Most of us with Usher syndrome are also losing our vision. The lip reading I depend on? I can’t always see your lips. They move too fast for eyes that can’t track motion anymore.

And just about everywhere people hang out is dark. Bars, restaurants, movie theaters, concerts. The places the hearing world goes to be social are the exact places where I can’t see your face AND can’t hear your voice. Both systems failing at the same time, in the same room.

I know that’s hard to read. It’s harder to live it.

OK. Back to the essay. On top of everything I just described, every device in the chain makes it worse. Phone speaker to hearing aid, TV across the room to hearing aid, each layer adds noise to an already bad signal. A bad signal amplified is a worse signal, not a better one. That’s why Bluetooth was a game changer for us. Sound goes straight from the phone or TV to the hearing aid or cochlear implant without passing through the air. One less layer of mess.

And if you went to speech therapy, you know the hardest part. They ask you to make sounds with your mouth that you have never heard. Think about that for a second. That’s like someone describing what a pangolin sounds like and then asking you to do it. You’ve never heard one. Now make the sound. That’s speech therapy for us.

The Three Types

Not all Usher syndrome is the same. The type you have determines which keys are missing, how many you start with, and whether you keep losing more. What I’m about to describe is the basic picture of each type, roughly what things look like by the late teens as a reference point. Type 1 and Type 3 can vary a lot, and the lines between the types aren’t as clean as the textbooks say. I’ll get deeper into each type in a later essay. For now, this is the overview.

thin Type 1: The switches are broken.
The tip link proteins (the connections at the top of the hair cells) are broken or never formed. The hairs splay outward in all directions like fingers spreading. Some switches stuck on, some stuck off. No coordinated signal. Profound deaf from birth.

Some people with Type 1 do have a little hearing early on, but it fades fast because the protein that maintains the switches is also the one that keeps them working day to day.

Hearing aids can’t fix this. No amount of louder helps when the hairs are a mess. That’s why most people with Type 1 get cochlear implants (CI). A CI bypasses the hairs entirely and sends electrical pulses directly to the hearing nerve, doing what the hairs would have done.

Type 2: The foundation is weak.
The ankle link proteins (connections at the base) are malformed. The switches at the top work fine. But the whole structure is leaning because the base is soft. Like a light switch mounted on a wobbly wall. You can still flip it but sometimes it catches, sometimes it doesn’t. The signal gets through, but it’s messy.

Hearing aids help by pushing the sound louder to overcome the lean. It takes more energy to trigger a switch when the thing it’s mounted on isn’t stable. That’s why we need powerful hearing aids. And it stays about the same. The foundation doesn’t keep getting weaker. Your hearing loss is severe, but it’s stable.

Type 3: Everything fails over time.
Everything works at first. The hair cells grow normally, the connections form, the signals fire. But over time, the protein that sustains the cells (clarin-1) can’t keep up. The hair cells degrade and die. You start with most of your hearing and lose it over time. This is the rarest type, and the hardest to plan around because nobody knows how fast it will go.

Types 1 and 2 have broken parts from the start. Type 3 has a broken maintenance system. That’s the difference.

What tends to help, and when:

Hearing is a spectrum, just like vision. No two people hear exactly the same even with the same type. What I’m about to say is the general picture, not a rule.

Type 1 usually needs cochlear implants early. The earlier the better for the brain to learn what to do with the signal. Hearing aids alone can’t overcome the damage.

Type 2 usually does well with hearing aids for most of life. Powerful ones. The aids push louder to overcome the leaning hair cells. At some point, usually later in life, the hearing aid ceiling gets close and the CI conversation starts.

Type 3 is the hardest to plan for. Hearing aids work at first, then need to keep getting stronger as the hearing drops. The timing of when to switch to CI depends on how fast it’s going, and nobody can predict that.

All of this should be done with an audiologist, not a hearing aid dispenser. I’m not putting dispensers down. Places like Costco are great for people with age-related hearing loss who had good hearing most of their life. But for USH, you need a doctor who understands the kind of damage we’re dealing with. It’s a different problem.

And while I’m on that subject, people always ask why our hearing aids cost 3 to 5 times more. It’s not just “louder.” Think of it this way. Go buy a nice cheap Bluetooth speaker. Sounds great in your living room. Now take that same speaker outside to a loud party, turn it to max, and try to hear someone talking over a crowd. It sounds terrible. It distorts. It can’t handle it. It wasn’t built for that. Now look at a professional speaker system that costs ten times more that handles a party no problem. Clear at high volume, cuts through noise, doesn’t distort. That’s the difference between a basic hearing aid and what we need. Our aids have to run at extreme power without distorting, suppress feedback, separate speech from noise, all in something the size of a fingertip. That’s deep engineering, and it costs what it costs.

And here’s what makes it worse. Insurance and most workplace plans still lump us in with age-related hearing loss. They cover the cheap speaker when we need the professional system. The hearing aids we need cost thousands, not hundreds. Most of us with USH don’t have high-paying jobs. Some don’t have jobs at all. And hearing aids are just one cost. Add to that the retina specialists, the cornea doctors, the scleral lenses, the low vision evaluations. I’ve worked full time my entire adult life. I’m in meetings every day. I hear and talk and contribute because of these hearing aids. My insurance still doesn’t cover them. Apparently they’re “nice to have.” Without them I can’t do the job. With them, I pay for them myself. Either way, we lose. USH is expensive to live with, and the system hasn’t caught up to what it actually takes. If you’re outside the US, I hope your country does a better job covering this. Here in the states, there’s no federal law that requires insurance to cover hearing aids.

One thing to know about cochlear implants: it’s not something you can undo. The surgery destroys most of the remaining hair cells in that ear. Once you go CI, you can’t go back to hearing aids in that ear. That’s why the timing matters so much. A hearing aid amplifies what you have. A CI replaces it entirely with electrical pulses. Both are doing the same job – getting sound to the brain – but through completely different paths.

For all three types, the earlier you act, the better the brain adapts. The brain learns to use whatever signal it gets. Wait too long and it gets harder.

Each type also has subtypes based on which specific gene is involved. Type 1 alone has five different genes (USH1B, 1C, 1D, 1F, 1G). Type 2 has three. Type 3 has one. The gene matters because it determines which treatments might work for you in the future. That’s a whole separate topic and I’ll get into it in a later essay about knowing your gene.

If you want to know a little more about each type, I have some extra notes at the end of this essay. And for how the types cross over and what the genes actually do, that’ll be a later essay.

Why It Seems to Get Worse

If Type 2 is stable, why does it feel like my hearing is getting worse in my 50s?

Melinda is Type 2, in her 50s, and she asked me: “Am I imagining it, or is my hearing getting worse?” My friend Bart isn’t even USH. He’s just hard of hearing, same loss as me, same aids for 30 years. He says it’s harder now too. We’re both 58.

But our hearing tests (audiograms) haven’t really changed that much. What changed is us. Our brains are slower. The world got noisier. And the keys we still have are tired. They’ve been carrying the whole piano for over fifty years.

This matters because it changes what you do about it. If the gene is progressing, there’s not much to try right now. If it’s the brain aging, there are things that help. Better hearing aids. Auditory training. Knowing when it’s time to talk about a cochlear implant. The answer to “is my hearing getting worse?” might be: your USH2 hasn’t changed, but your brain’s ability to work with that messy signal is declining with age. That’s a different problem with different solutions.

Nobody tracks any of this. Everyone shares their experience. Nobody shares their variables. Age at loss. Age at testing. What they heard before. What they hear after. How long between. One ear or both. What brand of aid, what settings, what environment. Without those numbers, community advice is just anecdotes arguing with each other. The data gap for hearing in Usher syndrome is the same gap I found in the vision research: everyone has pieces of the answer, nobody is putting them together.

Hearing loss is the invisible tax. You can see that someone uses a cane. You can’t see that their brain is burning through its daily budget just to follow a conversation at lunch.

The Window Is Small

When you have both conditions, hearing isn’t a preference. It’s your remaining lifeline.

As RP takes peripheral vision, your brain leans harder on sound for spatial awareness. Where is the door? Is someone behind me? Did I leave the water running? Normal peripheral vision handles most of that without you thinking about it. When it’s gone, sound picks up the slack. And when the sound is already damaged by hearing loss, the slack isn’t much.

I have about 30-35 decibels of headroom. My hearing loss sits around 97-100 dB (that’s severe-to-profound). My hearing aids, running UltraPower receivers, max out around 132 dB. That’s the absolute ceiling of what hearing aid technology can deliver. Normal hearing uses about 100 dB of range. I work with a third of that.

Put my hearing aid on a normal-hearing person and you’d cause immediate permanent damage. The aid puts out over 130 dB. That’s a jackhammer at one meter. OSHA won’t let workers near 115 dB for more than 15 minutes. But for someone with my loss, 130 dB is Tuesday.

The window between “can’t hear it” and “hearing aid can’t go louder” is small. And it’s all I’ve got. When that window closes, the next step is a cochlear implant. I’m not there yet. But I’m at the edge.

The Forgotten Sense

People ask about my vision. They don’t ask about my hearing.

Maybe it’s because hearing loss doesn’t look dramatic. There’s no cane, no dark glasses, no white-knuckle moment at the crosswalk. I’m in a meeting, I’m nodding, I seem fine. What they don’t see is the engine running at full speed underneath, trying to build whole words out of missing keys, guessing what you said, hoping I guessed right, all while also tracking what my eyes can’t.

Hearing loss in Usher syndrome isn’t just “turn it up louder.” Louder doesn’t bring back keys that were never there. It’s an invisible tax that compounds with the invisible tax of losing vision. Two systems failing independently but experienced together.

Tom was right. Hearing is the forgotten plain Jane. But for those of us living with both, it’s the sense we can’t afford to forget.

To my deaf and hard of hearing friends without USH, a lot of what I wrote here is your life too. I’m working on something just for you.

OK. I always tell myself I’m going to keep these essays short. I always fail. Sorry about that. If you’re done, you can stop here. If you want to know a little more about what’s different for Type 1 and Type 3, I have a bit more below. It’s not the full story on each type. I’m still learning when to cut my losses and stop writing.

A Bit More on Type 2

Not much more to say. That’s actually the point. Type 2 hearing stays about the same most of our lives. The essay you just read is mostly written from that perspective. The changes we feel in our 50s and beyond are more about aging than the gene. I covered that above.

A Bit More on Type 1

Most people with Type 1 are profoundly deaf from birth or very close to it. But it’s not always zero from day one. Some have a little hearing early on that fades fast. The protein that builds the tip links (the switches) is the same protein that maintains them. So even if they form partially, they break down without ongoing maintenance.

Cochlear implants are the main path for Type 1. The earlier the better. Tom got his first CI in 2002. It took twelve years before voices and music clicked. His second CI in 2025 merged with the first in one hour. The brain already knew how. That’s the timing argument in one story. First time is slow. Second time is fast. And every year you wait makes the first time harder.

A Bit More on Type 3

Type 3 is the hardest to live with in some ways because you don’t know what’s coming. You start with good hearing. It works. Then it starts to go and nobody can tell you how fast. Some lose it over a decade. Some over decades. Some hold on longer than expected.

The hearing aids that worked last year might not work next year. The settings keep changing. The audiologist keeps adjusting. And you keep asking the question nobody can answer: when does this stop? For Type 1 and Type 2, the answer is simple. Type 1 starts deaf. Type 2 stays about the same. Type 3 is the one where you’re always watching, always wondering.

I’m working on an essay about how hearing aids and cochlear implants actually work, what to look for, what to ask your doctor, and when you need one or the other. If that’s something you’d want to read, let me know.

Mark G. Hubers -- Just an Engineer with USH
https://ushengineer.substack.com

Researched and written: February 22, 2026 | Rev B — March 12, 2026

If you have retinitis pigmentosa, you’ve probably heard this advice: take 15,000 IU of vitamin A palmitate — a specific supplemental form of vitamin A — every day. Your doctor may have told you. A website may have told you. The National Eye Institute still tells you right now, today, on their website.

I still see it in Facebook groups and community chats. Someone asks what they can do, and the replies come: “Take vitamin A.” “My doctor put me on it years ago.” “It’s the one thing that might help.” People share this advice because they are trying to help. Because for thirty years, it was the one thing you could DO.

That recommendation is based on a single study from 1993.

In 2023, researchers at Harvard went back to that same data and did something nobody had done before. They broke it down by gene. Not “RP patients” as one group — but which RP gene each person actually had. 587 patients. 53 different genes identified.

What they found should have changed everything.

What the 1993 Study Said

In 1993, Dr. Eliot Berson at Harvard published a landmark trial. 601 people with RP. Four to six years of follow-up. His conclusion: 15,000 IU of vitamin A palmitate per day slowed vision loss. Avoid vitamin E — it made things worse.

That became the standard advice. For thirty years, retinal specialists prescribed vitamin A to RP patients. The National Eye Institute put it on their website. Patient organizations repeated it. It became one of the few things you could actually DO.

And it made sense at the time. In 1993, genetic testing for RP barely existed. You could not easily tell one form of RP from another just by looking at the retina. So they treated “RP” as one disease and measured whether the whole group did better on vitamin A. The average said yes — a small but measurable slowing of decline on the electroretinogram (ERG), which measures how much electrical signal your retina produces.

The problem is that average was hiding something. When you mix hundreds of people with dozens of different genetic causes into one group, the numbers blur together. One gene might be getting worse. Another might be staying flat. Another might be declining slowly for reasons that have nothing to do with the vitamin. Average them all and the math can say “small positive effect” even if no individual group is truly benefiting. That is what happened here.

That is exactly what happened. When the 2023 team broke the same data apart by gene, the benefit vanished. The only genotype that even hinted at a positive response was one specific mutation in the rhodopsin gene (RHO P23H) — and even that was not statistically significant. Every other gene showed either no effect or harm.

But by then the advice had been baked into medical guidelines, government websites, and doctor visits for three decades. Most of us never got a handout. Most of us had to ask. You sit in the chair, you hear the news, and you say “is there anything I can do?” And they say “well, there is vitamin A.” And you trust it because what else are you going to do. Or your family goes home and searches for answers — and the first thing they find is that same advice on every website. Nobody went back to check because nobody had the genetic tools to ask the right question until now.

Nobody asked: does it work the same for every gene? Including me. I took it too. I will get to that.

What the 2023 Study Found

Thirty years later, a team at the same institution — Mass Eye and Ear, Harvard — went back to the original trial data with modern genetic tools. They sequenced the DNA of 765 patients from those original trials and identified the specific gene causing each person’s RP.

Two findings. Both bad. One worse.

First: vitamin A does not help any form of RP. Not Usher syndrome type 1. Not type 2. Not type 3. Not non-syndromic RP. None of them. When they broke the data down by gene, there was no genotype that showed a clear, lasting benefit from vitamin A. Thirty years of advice, and it did not hold up.

Second: for one group — the biggest one — vitamin A did not just fail to help. It made things worse.

That group is USH2A. 65 patients in the progression analysis — the largest single genetic subgroup. The most common genetic cause of both Usher syndrome and non-syndromic RP.

For USH2A patients, vitamin A showed a statistically significant adverse effect — the group taking it declined faster than the group that did not.

A few things to understand about this finding. USH2A is not one thing. There are over 1,200 known pathogenic variants in the USH2A gene. This study grouped them all together. It was also a subgroup analysis — meaning the researchers went back into the original trial and looked at one piece of the larger group. That kind of analysis does not carry the same weight as a dedicated trial.

The researchers themselves acknowledged this. In their own words: “We speculate that if a large study was conducted in any specific subgroup, then the potential adverse effects would be unlikely to be replicated.” They knew the limitations.

But they also said this: “Notwithstanding the many limitations of any statistical test, the final statistical calculation was well powered to detect an effect of vitamin A in the USH2A subgroup, and the observed effect was adverse.”

For those who want the numbers: the measure of how much worse they did (regression coefficient) was -0.04 — negative means the vitamin A group declined faster. The chance this happened by coincidence (P value) was 2%. In research, if that number is under 5%, the result counts as real. Two percent is real. The effect was small. But it was there.

Knowing all of that, the researchers did not hedge their recommendation. Their exact words:

“For patients with RP associated with USH2A mutations who are on vitamin A supplements, we make a recommendation to stop supplementation.”

Let me be clear about who this affects:

If you have USH2A (Usher syndrome type 2A or USH2A-related RP): The data showed a statistically significant adverse effect. The researchers say stop. Bring the study to your doctor and have the conversation.

If you have a different type of RP or Usher syndrome (USH1, USH3, other genes): The data says vitamin A does not help. It showed no overall benefit for any genotype. The researchers stopped recommending it for all new RP diagnoses and for children with RP.

If you do not know your genotype: That is part of the problem. You might be taking a supplement that is hurting you and not even know it because nobody tested your DNA.

Their current position applies to everyone: “We currently do not recommend vitamin A or E supplementation for patients with RP.”

Where the Information Stopped

Here is where it gets bad.

That paper was published in August 2023. It has been over two years. Here is what happened to the USH2A finding as it traveled from the researchers to the patients:

The researchers said it clearly. Stop vitamin A if you have USH2A.

The Foundation Fighting Blindness covered the study. They reported “no overall benefit from vitamin A.” They did not mention the USH2A-specific harm.

The Usher Syndrome Coalition covered the study. They said vitamin A was “not effective enough to recommend.” They did not warn their USH2A community that it may be actively harmful.

Retina UK covered the study. They said patients already on vitamin A could continue under supervision. No USH2A warning.

The National Eye Institute page still says vitamin A “may help slow vision loss.” When I first found it, that page had not been updated since 2008. It has since been updated — August 2025 — two full years after the Harvard study was published. Someone touched that page and still did not add the finding. No mention of the 2023 study. No mention of genotype-specific effects. No warning for USH2A. It is the first result many patients find when they search for help.

GeneReviews — the clinical reference doctors actually use to look up Usher syndrome — still says vitamin A “may limit progression” for USH2. That entry was last updated in March 2023, five months before the paper was published.

I looked for patient-facing resources that specifically say “if you have USH2A, stop taking vitamin A.” I searched patient forums. Facebook groups. Reddit. Blue Book. Organization websites. Doctor Q&A pages.

I found nothing. Not one.

The researchers said stop. The information never reached the people who need it.

I am not blaming these organizations. I respect what they do and I want to find ways to help. They are small teams doing important work with limited resources. Monitoring every study and pushing genotype-specific updates to every patient who needs them is a massive job. Nobody has figured out how to do it well yet.

But the gap is real. A finding this important should not sit in a journal for two years without reaching the people it is about. Someone needs to read these studies, put them in plain language, and get them in front of the community. Someone needs to check back and make sure the information stays current. That is all I am trying to do here.

“It Can Only Help or Do Nothing”

That is what most people think about supplements. Vitamins are natural. They support your body. Worst case, you pee out what you do not need. Right?

That is the assumption. And for most healthy people taking a daily multivitamin, it is probably close enough to true.

But for RP patients taking high-dose vitamin A — 15,000 IU per day, ten times the recommended daily amount for a healthy adult — it was never that simple. This is not a multivitamin. This is a therapeutic dose based on a specific clinical trial. And when the researchers went back and checked who it was actually helping, the answer was: nobody. And for USH2A, the largest group, it was doing the opposite of helping.

I still see this assumption in Facebook groups and community chats. Someone asks about supplements, and the replies come in: “I take vitamin A, my doctor said it might slow things down.” “Can’t hurt to try.” “I’ve been on it for years.”

It can hurt. The data says so. And the reason nobody knows is that the people who found it did not get the word out far enough.

Why This Matters Right Now

This is not a minor footnote about a rare subtype.

USH2A is the most common cause of Usher syndrome — about half of all cases. It is also one of the most common causes of non-syndromic RP. When the researchers broke their data down by gene, USH2A was the single largest group. Nearly one in four genotyped participants.

For that group — the biggest one — vitamin A is harmful.

For everyone else with RP, vitamin A does not help.

Either way, the thirty-year-old advice was wrong. Some people are taking a supplement that does nothing. Some are taking one that is making things worse. And both groups are doing it because nobody updated the recommendation.

What About Vitamin E?

The original 1993 study found vitamin E was harmful to RP patients. The 2023 re-analysis confirmed it across all genotypes. This matters because AREDS2 — the supplement formula commonly recommended for age-related macular degeneration — contains 400 IU of vitamin E.

If you have RP and someone recommends AREDS2 for your eyes, that formula was designed for a different disease. The vitamin E in it may accelerate your vision loss. Two eye conditions, two supplement recommendations, and they directly contradict each other. Nobody connects the dots because nobody is looking at both diseases in the same patient. This is the kind of thing that gets to me — people following advice that sounds right but nobody checked the facts behind it.

What Else Is Out There

Not everything is bad news. But after what you just read, you deserve honesty about what we know and what we do not:

Lutein (12 mg/day): One trial of 225 patients (Berson, 2010) showed modest preservation of mid-peripheral visual field. No harm found. I had not heard of this one until I started researching for this essay — and that is part of the problem. But here is what I ran into while checking it: that trial was done the same way as the 1993 vitamin A study. All RP patients in one group. No breakdown by gene. We just spent half this essay explaining why that method hid the truth about vitamin A. I cannot tell you lutein is safe for every genotype because nobody has checked. It is the supplement with the least concerning data right now, but “no harm found in the average” is exactly what they said about vitamin A for thirty years.

I almost let this slide myself. I wrote this section, reviewed it multiple times, and did not catch the contradiction until I read it again and thought: wait — did anyone check this by gene? They did not. The same gap I am writing about almost made it into my own essay. So I am not going to tell you lutein is safe for your gene. What I will say is that someone needs to do what the 2023 team did for vitamin A — go back and break the lutein data down by genotype. Until then, the people most likely to try it are the ones who feel they do not have much left to lose. That is how a lot of us learn what works. And that is a sad fact about where we are right now.

NAC (N-acetylcysteine): Targets the oxidative cascade that kills cone photoreceptors after rods die. A Phase 3 trial with 483 patients across 31 sites is actively recruiting. NAC is also available over the counter. Ask your retinal specialist.

Omega-3 from diet: Eating one to two servings of oily fish per week was associated with slower decline in the original studies. Diet-based, not mega-dose supplements. And unlike the others on this list, omega-3 from fish is good for your heart, your brain, and your joints too — so even if the retina benefit is small, you are not wasting your time. I just learned the brain part while writing this. Given how much brain power these essays take, I should probably eat more fish.

How I Found This

I did not set out to research this. I have USH2A. Two different mutations in the same gene, both broken — what genetics calls compound heterozygous. Those are the two they have found so far. Every time a doctor looks, they find something else. I have stopped asking.

I took vitamin A too. About a year. I stopped — not because I knew about this study, but because I never trusted it. Most supplements are not studied. I am not here to debate that. But I took it because my family said “do anything to help.” And when someone you love is watching you lose your vision, you do things for them more than for yourself. I got tired of taking something I did not believe in, so I stopped. Turns out that was the right call.

I mention this because I know the pressure. It is not just doctors recommending it. It is the people around you who need to feel like something is being done. That is real. And it makes it harder to stop even when the evidence says you should.

A friend emailed me about his 80-year-old friend who had been told he had macular degeneration for forty years. A new retinal specialist said it was actually RP. The doctors were contradicting each other and his friend did not know who to believe.

I started looking into whether RP patients can also get age-related macular degeneration as they age. That led me to supplements. That led me to the AREDS2 question. That led me to the 2023 Harvard study. That led me to the realization that nobody told us.

One email. One question from a friend about his friend. And here we are.

Here is the part I did not expect.

When I shared what I found, my friend wrote back. He had been taking vitamin A himself. His blood test in December showed elevated levels and his doctor told him to stop temporarily. He was planning to restart after his next blood test in May.

He is not restarting now.

His question about his 80-year-old friend led to the research that is now protecting him. He had no idea he was helping himself by asking about someone else.

This is what community does. We ask each other questions. And sometimes those questions lead somewhere nobody expected — including right back to ourselves.

We Are Getting Better at This

I do not want this essay to sound like everything is broken and nobody cares. That is not true.

The reason the 2023 study exists at all is because genetic tools caught up. In 1993, you could not sequence a patient’s DNA for a reasonable cost. Today you can spit in a tube and know your exact mutations in a few weeks. That is real progress. The science IS getting more precise. Treatments ARE becoming genotype-specific. The era of “all RP is the same” is ending.

The problem is not the science. The problem is the lag between what researchers find and what patients hear. A study gets published. An organization summarizes it. A website does not get updated. A doctor reads the old guideline. A patient takes what they are told to take.

That lag is shrinking. Genetic testing is more accessible. Patient communities share information faster than journals ever could. People like the ones reading this are asking better questions and demanding better answers.

But we are not there yet. The NEI page was updated in 2025 and still says vitamin A may help — two years after the study said otherwise. GeneReviews still says vitamin A may help. And somewhere right now, someone with USH2A is taking a supplement they believe is protecting their vision.

We need to close that gap faster.

What You Should Do

I am not a doctor. I am not telling you to stop taking anything. I am telling you what a 2023 study from Harvard found, and what the researchers who ran it now recommend.

If you have USH2A and you are taking vitamin A: The data showed a statistically significant harmful effect. The researchers explicitly said to stop. Bring the study to your retinal specialist and have the conversation.

If you have a different form of RP and you are taking vitamin A: The data showed no benefit. The researchers no longer recommend it for any RP patient. Same advice — bring it to your doctor and decide together.

If you do not know your genotype: That is the first thing to fix. You might be taking something that is hurting you and not know it because nobody tested your DNA. A genetic test can tell you. GeneDx and Invitae both offer retinal disease panels. Insurance usually covers it. The Foundation Fighting Blindness has a program called My Retina Tracker that can help you get tested.

Know your gene. Then decide what to put in your body. I wish someone had told me that thirty years ago.

What This Does NOT Mean

If you took vitamin A for years and you have USH2A — do not panic. The adverse effect found in this study was small. This was one re-analysis of one trial, using a subgroup of 65 people. It is a signal, not a sentence.

It does not mean vitamin A poisoned you. It does not mean years of supplementation caused major damage. It means the data showed a small but real negative effect, and the researchers who found it said to stop. That is what you should know. That is what you should bring to your doctor.

If you gave vitamin A to your child because a doctor recommended it, you did what any good parent would do. You followed the best advice available at the time. The science changed. The advice should change with it. That is not your fault.

The point of this essay is not to scare anyone. The point is that the information should have reached you sooner.

A Note on Getting It Right

I care about accuracy more than being first. Everything in this essay is sourced from published, peer-reviewed research. The links are below so you can read the original studies yourself.

If I got something wrong, tell me. Send me the study. I will update this, note what changed, and credit you for the correction. I would rather be corrected than spread bad information.

This essay is dated and revisioned. That is not decoration. You just read about a government health page that went seventeen years without an update, got updated, and still did not include a major finding. Dates matter. Revisions matter. If the science changes, check my revision history — the essay changes with it.

Sources

Comander J, Weigel DiFranco C, Sanderson K, et al. Natural history of retinitis pigmentosa based on genotype, vitamin A/E supplementation, and an electroretinogram biomarker. JCI Insight. 2023;8(15):e167546.

Published August 8, 2023. DOI: 10.1172/jci.insight.167546

Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Archives of Ophthalmology. 1993;111(6):761-772.

Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Archives of Ophthalmology. 2010;128(4):403-411.

Foundation Fighting Blindness. “New Report: Vitamin A Supplementation Provides No Vision Benefit to RP Patients.” November 2, 2023.

National Eye Institute. “Retinitis Pigmentosa.” Last modified August 6, 2025. Still states vitamin A “may help slow vision loss” without referencing the 2023 genotype-specific findings.

Acknowledgment: This essay exists because Brian Viens emailed me about his friend. One question led to all of this. Thank you, Brian, for asking the right question.

Mark G. Hubers — Just an Engineer with USH

Revision history:

Draft v1 — February 22, 2026

Rev B — March 12, 2026: Added researchers’ own caveats about subgroup analysis limitations. Noted USH2A heterogeneity (1,200+ variants). Softened language to match what the data actually showed. Added “What This Does NOT Mean” section addressing guilt and fear. Thanks to Dr. Paul Glover (USH Coalition Ambassador, NZ) for the feedback that made this revision better.

Have a correction? Reach me through Substack or the USH Blue Book.

Someone recently asked whether Germany has the most people with Usher syndrome (USH). I didn’t know the answer. And I realized I’ve been deep in treatment pipelines and clinical trials for months now, but I’ve never actually looked at the basic question: where are we? How many of us are there? Who gets this?

I’ve had bits and pieces of this data floating around in my head for a while; carrier rates, the Jewish connection, a few numbers here and there. I always thought it would make a good topic to pull together. So I finally did. And honestly, even I was surprised by what came back.

Since I first published this essay, readers from India, the UK, South Africa, and across the US have sent me data I didn’t have. Researchers I’ve never met. Parents who tracked down studies I missed. That’s what happens when you say “I want to hear it” and mean it. This version includes everything I’ve learned since.

Fair warning, I am just an engineer with Usher syndrome, so this is a data dig, not a research paper. If anyone has better data or corrections, I want to hear it.

Data on how common USH is (prevalence) is really hard to come by. Most countries don’t track it. A huge number of people are undiagnosed or misdiagnosed. The studies that exist are small, regional, and some are decades old. So these are the best numbers I could find as of April 2026, not the final word. If anything, the real numbers are probably higher.

How Many of Us Are There?

There are somewhere between 400,000 and 720,000 people living with Usher syndrome worldwide. That’s a massive range, and the reason is simple. Most people with USH are never properly diagnosed.

A 2025 genomic study (Redfield et al.) came at it differently. Instead of counting diagnosed patients, they looked at how often USH gene variants actually appear in human DNA. Their number: 721,769. That includes everyone; diagnosed, undiagnosed, people who have no idea what’s coming.

About 12,000 babies are born with USH every year worldwide. Roughly 324 in the US.

And here’s the one that stopped me cold: 1 in 100 people carry a pathogenic USH variant, meaning a broken copy of a USH gene that can cause the condition. They’ll never know unless they have a child with another carrier. Let that sit for a second. One in a hundred people you pass on the street. About 80 million carriers worldwide.

So why aren’t there millions more of us? Because USH is recessive. Both parents have to carry a broken copy. The odds of two carriers finding each other: 1 in 100 times 1 in 100 = 1 in 10,000 couples. And even then, each child only has a 25% chance. Do the math: 1 in 10,000 times 1 in 4 = roughly 1 in 40,000. That’s close to the observed rate of about 1 in 29,000. The carriers are everywhere. The disease is rare because it takes two.

Think of it like a wiring defect. One in a hundred people are walking around with one bad wire. They’ll never know. The backup wire handles it fine. But if two people with the same faulty wire have a child who inherits both bad copies? No backup. That’s USH.

So Where Is USH Highest?

Country / Region USH Rate Notes Margarita Island, Venezuela ~76 per 100,000 Isolated community. 22x the global average. Sweden ~1 in 10,000 Highest documented national rate Germany ~1 in 16,000 2002 Heidelberg study India (Southern states) ~20 per 100,000 Hospital-based, not population-based. High consanguinity in South. USA ~1 in 25,000 ~30,400 people estimated Norway ~1 in 28,000 ~400 estimated undiagnosed Japan ~0.4 per 100,000 2021 study, called it a minimum Pakistan Not well studied MYO7A dominant (not USH2A). High consanguinity.

Sweden holds the highest documented national rate: 1 in 10,000. That might be because Sweden is better at tracking it, not because they have more of it. Hard to say.

Germany: 1 in 16,000 (from a 2002 Heidelberg study). So the claim about Germany being high is real. But Sweden’s rate is higher, and the US likely has more total people with USH just because of population size.

And then there’s Margarita Island, Venezuela. 76 per 100,000. I had to read that three times. A small, isolated community where one ancestor carried a mutation in a gene called MYO7A (one of the main USH1 genes) and everyone married locally for generations. The carriers didn’t spread out. They stayed, and the odds of two carriers having kids went way up. Twenty-two times the global average. That’s what recessive genetics does when carriers stay in one place.

When you zoom out to whole countries though, large mixed populations, the rates mostly level back out to around 1 in 25,000 to 1 in 40,000. That’s roughly what the carrier math predicts. The hot spots aren’t breaking the math. They’re showing what happens when carriers stop being random and start being neighbors.

And I want to be clear about something. If you’re from one of these communities, this is not why you have USH. These patterns built up over many generations when moving far from home wasn’t easy and marrying within the community was just how life worked. Today, consanguinity rates are dropping in most of the world. The mutations that concentrated over centuries are still there, but the pattern that concentrated them is fading. This is history, not blame.

How Old Are These Genes?

This is the part that changed how I think about USH.

The genes that cause Usher syndrome are not human genes. I mean, they’re in our DNA. But they didn’t start with us. Not even close.

USH2A, the gene that’s broken in me, has relatives in sea urchins. Sea urchins don’t have eyes. They don’t have ears. But 500 million years ago, the protein that USH2A makes was already doing something important enough that evolution kept it around. Every vertebrate since has carried a version of it.

MYO7A, the most common USH1 gene, works in fruit flies. The fly version is called “crinkled.” If you knock it out, the fly goes deaf. Its hearing organs detach. That means the hearing function of this gene is at least 600 million years old. Before vertebrates. Before anything had an ear the way we think of ears.

The genes are ancient. The mutations are recent.

The most common USH2A mutation in humans, a deletion called c.2299delG, has been traced to a single ancestor who lived in Europe about 5,000 to 7,000 years ago. One person. One mutation. Today it shows up in patients across 14 countries. You can literally trace one person’s DNA change spreading across a continent over thousands of years.

When What ~600 million years ago MYO7A ancestors working in invertebrate sensory systems ~500 million years ago USH2A structural role established before the vertebrate/sea urchin split ~5,000-7,000 years ago c.2299delG arises in Europe (Neolithic/Bronze Age) ~2,000-4,000 years ago Finnish CLRN1 mutation concentrates during isolation ~500-1,000 years ago PCDH15 R245X concentrates in Ashkenazi Jewish communities ~400 years ago USH1C mutation carried to the New World by French settlers 1858 Albrecht von Graefe first describes the condition clinically 1914 Charles Usher names the syndrome 1995 First USH gene (MYO7A) identified

We carry ancient genes with recent breaks. The machinery is half a billion years old. The damage is a few thousand years old at most.

The Ancestry Piece – This Is Where It Got Interesting

I went into this thinking USH was USH. Same disease everywhere. It is not.

USH is a collection of mutations that ended up causing the same thing. And certain mutations got concentrated in certain populations because of how humans migrated, married within their communities, and stayed put. Your ancestry isn’t just background info, it shapes which mutation you carry and which treatments might work for you.

Ashkenazi Jewish communities have elevated rates of both USH1 and USH3. One specific DNA change in a gene called PCDH15 (mutation R245X) has a carrier frequency of 1-2.5% depending on the population studied. To put that in perspective: if 1 in 100 is the general carrier rate, parts of the Ashkenazi population are running at 2.5 in 100. That changes the math fast.

In Finland, USH3 accounts for 40% of all USH cases. Everywhere else in the world it’s 2-5%. One mutation called “Finmajor” is responsible. Finland has a whole set of rare diseases that concentrated over centuries of geographic isolation; they call it the Finnish disease heritage.

In French-Acadian and Cajun populations, one single DNA change in the USH1C gene (c.216G>A) accounts for 90% of their USH1. It traces back to the families expelled from Nova Scotia in 1755. Southwest Louisiana today has the largest deaf-blind community in the United States because of it. Think about that. A forced migration 270 years ago is still showing up in people’s DNA.

For Europeans in general, the most common USH2 mutation worldwide is a specific deletion in the USH2A gene (c.2299delG). It accounts for about a third of USH2 cases across Germany, France, and European-Americans. If you have European ancestry and USH2, there’s a decent chance this one’s involved.

And in East Asia, a completely different mutation passed down from a common ancestor (a founder mutation) shows up in Chinese and Japanese populations that has never been found in Europeans. Different continent, different mutation, same disease.

In 2025, a large study from Pakistan found that MYO7A is the dominant USH gene there. Not USH2A. The exact opposite of Western populations. Pakistan has some of the highest consanguinity rates in the world, over 60% of marriages, and USH genetics there are just starting to be mapped. Same disease, completely different genetic path.

Founder Populations Most People Don’t Know About

Since the first version of this essay, I found data on populations that rarely make the USH conversation:

Indigenous South Africa. A single MYO7A mutation (c.6377delC) was found across three different ethnolinguistic groups: Xhosa, Zulu, and Sotho. All patients shared the same genetic fingerprint. One ancestor, before these groups diverged. That mutation is old. And here’s the problem: testing panels designed for European patients catch only 12.8% of indigenous African patients. Most African USH variants haven’t been catalogued yet.

North Africa and the Maghreb. Researchers in Tunisia, Algeria, Morocco, and Mauritania tested 450 deaf patients and found 211 different mutations. 36% had never been reported before. More than a third of the mutations were invisible to existing databases.

The Arabian Peninsula. A deep intronic CLRN1 mutation specific to the Arabian region causes severe USH3. It would be completely missed by standard genetic testing because it sits in a part of the DNA that most tests don’t even look at.

Non-Ashkenazi Jewish populations. Four distinct USH2A founder mutations that are different from the Ashkenazi variants. Different community, different mutations, same gene.

I’m Polish and Dutch heritage myself, and there’s no specific data for either population. But my USH2A mutations are consistent with the broader European pattern.

The Parts Nobody’s Talking About

Asia

Most of what I just covered is European, Jewish, and North American data. That’s not because USH doesn’t exist elsewhere. It’s because nobody’s looking.

Asia has over 4 billion people. India alone has 1.4 billion. China another 1.4 billion. Apply even a conservative USH rate to those numbers and you’re looking at potentially hundreds of thousands of people. Most of whom have never been genetically tested, never been properly diagnosed, and have no idea there’s a global community or clinical trials they might qualify for.

Since publishing this essay, I heard from an Usher syndrome ambassador in India. That conversation led me to dig deeper, and I found actual data. A study at the L V Prasad Eye Institute, one of the largest eye hospital networks in Southern India, found USH in 401 out of 2.5 million patients. That’s 2.6% of all their RP patients. The study covered hospitals in Telangana, Andhra Pradesh, Karnataka, and Odisha.

I need to be clear: those numbers are hospital-based, not population-based. They can’t be applied to all of India. India’s national family health survey shows consanguinity rates of 26-28% in the Southern states where this study was done. That’s more than double the national average of 10.8%. Northern India, where consanguinity is much lower, would likely look very different. Nobody has published those numbers yet.

Using the Redfield 2025 genomic data proportionally, India’s USH population is probably around 120,000 to 130,000 people. That would make India one of the largest USH populations in the world by sheer numbers. And almost none of them are in any registry.

The consanguinity connection is the same pattern we see everywhere else. In the general population, two strangers both carrying the same USH variant is a 1 in 10,000 chance. In a family that marries within itself, grandpa’s bad copy shows up on both sides. The matching problem disappears. It’s not different biology. It’s the same math with a smaller deck of cards.

China just screened millions of people for retinal disease, but nobody’s asking how many of those people have Usher syndrome specifically. Japan has at least some data: a 2021 nationwide study found a minimum rate of 0.4 per 100,000, but they called it a minimum because most cases go unreported. For most of South Asia and Southeast Asia, almost nothing exists in the published literature.

Native Americans

This is the gap that surprised me the most.

The published literature has exactly one documented Native American USH patient. A 2025 study from South Florida. 148 patients, diverse backgrounds. One American Indian or Alaska Native. Molecular testing was inconclusive.

One. In all the medical literature I could find.

But here’s what population genetics tells us: Native Americans experienced some of the most extreme founder bottlenecks in human history. Everyone descends from a small group that crossed the Bering land bridge about 15,000 years ago. All Native American mitochondrial DNA traces to just five founding maternal lineages. Five.

That’s the same kind of isolation event that concentrated USH in Finland, in the Ashkenazi community, in Acadian Louisiana. Different scale, same mechanism. If any of those five lineages carried a USH variant, drift could have amplified it in the founding population.

At the standard 1 in 29,000 rate, there should be about 235 Native Americans with USH in the United States. But over 96% of all hearing loss genetic studies are conducted on European or Asian subjects. Native Americans average 0.3 studies per year. The absence of evidence is not evidence of absence. Nobody’s looked.

Africa

Testing panels designed for European patients miss most African USH variants. Only 12.8% of indigenous African patients get a conclusive genetic diagnosis, compared to 41.1% for Caucasian patients. The testing exists. The variants in the tests don’t match the variants in the patients.

Dogs, Cats, and the Question Nobody Asks

This might be the most surprising part of this whole essay.

A community member asked me: “Why don’t wild animals seem to have diseases like USH?” The answer changed how I think about why this condition exists.

They do. You just never see them. Because they’re dead.

In the wild, a deaf animal can’t hear a predator. A blind animal can’t find food. An animal losing both at once is gone before it ever reproduces. Natural selection is brutally efficient on sensory loss. The affected animals are removed.

But the carriers, the ones with one good copy and one bad copy, are perfectly fine. Invisible. Natural selection can’t see a recessive carrier. The bad copy hides behind the good one and gets passed along quietly, generation after generation.

That’s why USH persists. Not because it’s an advantage. Not because it’s neutral. Because the carriers are invisible to selection, and there are 80 million of them.

Now look at what happens when you take natural selection out of the equation.

Dogs. Progressive retinal atrophy (the dog version of RP) is autosomal recessive in most breeds. It affects dozens of breeds including Labrador Retrievers, Cocker Spaniels, and Golden Retrievers. Hereditary deafness is documented in over 80 dog breeds. Dalmatians are the most famous, but it runs through Australian Shepherds, English Setters, and many more.

Cats. White cats with blue eyes: 65-85% are deaf in one or both ears. Congenital, sensorineural, linked to the same melanocyte biology that gives them their coat color.

Lab mice. The “shaker-1” mouse has a MYO7A mutation. The same gene as USH1B in humans. The mouse is born deaf with balance problems. It bobs its head and runs in circles. That behavior is how researchers found it. In the wild, that mouse would have been eaten in its first week. In a lab, it lives long enough to teach us about our own disease.

In 2023, researchers at Oregon Health and Science University created the first USH1B primate model using gene editing (CRISPR). A rhesus macaque with MYO7A mutations that mirror the human disease. That animal exists because we can now study USH in a species close enough to us that the results might actually translate to treatment.

The genes that cause USH are half a billion years old. Every species that has ears and eyes has some version of them. We didn’t get a new disease. We got old genes in a world where the rules changed. Humans broke the equation. Medicine and society removed the selective pressure. People with USH live full lives, have children, build careers. The condition persists not because something went wrong with evolution, but because we outgrew the part of evolution that would have stopped it.

The ICD-10 Milestone (and Its Limits)

As of October 2025, Usher syndrome has its own ICD-10-CM codes (Q99.811 through Q99.819). This matters for tracking. For the first time, doctors can code specifically for USH Type 1, Type 2, or Type 3. Before this, USH was lumped into generic categories. Diagnosis codes drive insurance coverage, research funding, and prevalence tracking.

But here’s the catch: there are no sub-codes for gene types. The system can count “how many Usher Type 2” but it cannot distinguish USH2A from USH2C. That matters because treatments are becoming gene-specific. Knowing there are 29,000 Type 2 patients in the US doesn’t help if you need to know how many of them carry the specific mutation your drug targets.

Gene-level tracking still requires registries like My Retina Tracker and Rare-X. Medical billing codes got us to the type level. The gene level is still a manual effort.

Male vs Female

There is no difference. USH is autosomal recessive, meaning it lives on one of the regular chromosomes, not on X or Y. Gender has nothing to do with it. Males and females are equally likely to carry it, have it, or pass it on.

The Type Breakdown

Type % of All USH US Patients (est.) Notes USH2 ~60% ~29,100 Most common. That’s where I am. USH1 ~25-35% ~2,800 Usually more severe, earlier onset USH3 2-5% ~66 Jumps to 40% in Finland and Ashkenazi Jewish communities USH4 Extremely rare – Recently recognized (ARSG gene). Still being studied.

Those US numbers come from Redfield et al. 2025, the same DNA-based study that estimated 721,769 worldwide. Look at USH3. 66 people in the entire United States. And there’s now a fourth type that’s barely been studied at all.

The Numbers That Hit Hardest

10% of all children born with hearing loss in both ears (bilateral) have Usher syndrome. Most are never tested for it.

50% of all deaf-blind people have Usher syndrome.

A 2025 study from South Florida looked at 148 USH patients from diverse backgrounds. White patients were significantly more likely to get a conclusive genetic diagnosis than non-white patients. The testing exists. It just doesn’t reach everyone equally.

India alone may have 120,000 to 130,000 people with USH. Almost none are in any registry or study.

Native Americans have virtually zero representation in USH genetic research. There should be about 235 people with USH among 6.8 million Native Americans. Nobody has looked.

The genes that cause USH are 500 to 600 million years old. Your dog might carry a version of the same broken gene. The shaker-1 mouse was named for the head-bobbing caused by the same gene that causes USH1B in humans.

Every USH family carries a piece of population genetics history in their DNA. The Acadian mutation traces a forced migration from 1755. The Finnish mutation maps centuries of isolation. The Ashkenazi mutations reflect centuries of marrying within close-knit Central and Eastern European Jewish communities. The South African mutation predates the divergence of the Xhosa, Zulu, and Sotho peoples. The European c.2299delG traces to one person who lived 5,000 to 7,000 years ago.

We’re not just patients. We’re walking history.

It was a good question and the numbers were too interesting not to share. Since publishing the first version, readers from four continents have sent me data, corrections, and studies I missed. That’s exactly what I hoped would happen.

If you have corrections, better data, or know of studies I missed, I want to hear it. This stuff should be compiled somewhere accessible, not buried in journals nobody reads.

~Mark

Sources: Redfield et al. 2025 (Am J Med Genet), Kimberling et al. 2010, Boughman et al. 1983, Grøndahl 1987 (Norway), Espinós et al. 1998 (Margarita Island), Joensuu et al. 2001 (Finland), D’Esposito et al. 2025 (Genes), Cromar et al. 2025 (Human Genomics), Nishiguchi et al. 2021 (Commun Biol), Pakistani IRD Cohort 2025 (npj Genomic Medicine), Parameswarappa et al. 2023 (LVPEI/APEDS), NFHS-5 2019-21 (India consanguinity data), Kannabiran et al. 2022 (Frontiers Genet), Aller et al. 2010 (Eur J Hum Genet), Dreyer et al. 2001 (Am J Hum Genet), Ebermann et al. 2007 (Hum Genet), Ebstein et al. 2015 (ARVO), Toms et al. 2015 (IOVS – South Africa), Slimani et al. 2025 (Maghreb), Moreno-Pelayo 2023 (Arabian CLRN1), Ben-Arie et al. 2000 (Drosophila MYO7A/crinkled), Strain 2011 (hereditary deafness in dogs), OHSU 2023 (CRISPR primate USH1B model), Achberger et al. 2019 (Ush2a zebrafish). Full citation list: essays/count/fact-check.md

I read 20/25 on an eye chart. Near-perfect acuity. But I see one to two words at a time through about 10 degrees of vision – down from a full wide-open view, and still shrinking. The eye chart says I’m fine. I can barely see the wall it’s hanging on.

And that 20/25 isn’t even what it looks like. My left eye is the sharper one. My right eye is closer to 20/40 – the cornea is too distorted to do better. Doctors call it a “lazy eye” but it’s not lazy. It’s damaged. When I use both eyes together, my brain combines two imperfect inputs and somehow produces something better than either one alone. Engineers call it sensor fusion. And honestly, it doesn’t even make sense to me. In my world – software, systems, engineering – you need at least three sources to get a better answer. Two disagree, the third breaks the tie. But my brain takes two broken signals with no tiebreaker and builds something sharper than either one. I do this for a living and I still can’t tell you how that works. Sorry – got off track. Back to plain English. 20/25 isn’t a measurement of what my eyes see. It’s a measurement of what my brain builds out of two broken signals. The system writes down one number and calls it my vision.

I know what you’re thinking. He’s got 20/25. He’s not blind. Keep reading.

That’s what retinitis pigmentosa does. It takes the periphery first and usually leaves the center for last. Other conditions can blur even that – in my case, keratoconus warps the cornea – but the center is typically the last thing to go. And it’s the first thing they test. And the entire medical system is built around that one number.

The Wrong Test

Here’s how a standard eye exam works. You sit in a chair, look at a chart on the wall, and read the smallest line you can see. The doctor writes down a number – 20/20, 20/25, 20/40 – and that number follows you everywhere. Insurance forms. Disability applications. Workplace accommodations. Driver’s license renewals. Prescription updates. That number IS your vision, as far as the system is concerned.

The problem is that number measures one thing: how sharp your center is. It says nothing about how much you can actually see.

Think of it this way. Imagine looking through a paper towel roll. The image at the end is perfectly clear. You could read a book through it. But you can’t see the room. You can’t see someone standing next to you. You can’t see the car coming from the left. The picture is clear enough to read. The window is almost gone.

Want to try it? Grab a toilet paper roll and hold it up to one eye. Close the other. Look across the room – about ten feet. That’s roughly 20 degrees of visual field, right at the legal blindness line. Now try a paper towel roll. That’s roughly 10 degrees – closer to what I have on a typical day.

It’s not a perfect simulation. What you see through the tube changes depending on how far away you’re looking – up close you see just a few inches, across the room you see a couple feet. My actual vision is more complicated than any tube can show: it shifts with lighting, fatigue, time of day, and my brain fills in gaps the tube can’t. But it gets the basic idea across. Walk around your house with that paper towel roll for five minutes. You’ll understand more about RP than most eye doctors explain in an hour.

That’s 20/25 with 10 degrees of field. Near-perfect acuity, legally blind. Both true at the same time. And nobody built a system that handles both being true at the same time.

There IS a test that measures what I actually lost. It’s called a visual field test (Goldmann or Humphrey). You look into a dome and click a button when you see a light flash on the sides. It maps how much peripheral vision you have left. That’s the test that matters for RP. That’s the one that shows I’m legally blind. It’s still not the whole picture – but at least it’s measuring what I’ve lost.

But it’s not the one they check first. It’s not the one on the forms. It’s not the one insurance or the system cares about. And in my experience, the equipment is often old, miscalibrated, and wrong. I’m an engineer. I can hear when a machine isn’t working right. I told them – more than once – “you know this thing isn’t working right.” They ran the test anyway. And the results said I was OK.

I wasn’t OK.

One Year for a Piece of Paper

It took me over a year to get my doctor’s technician to fill out a legal blindness form. Over a year. In a retina specialist’s office. A place that exists specifically for people like me.

She knew what 20/200 means – that’s the only definition of blindness she’d ever heard. Night blindness, field loss, none of that was on her radar. But the legal definition has two paths: either your best corrected acuity is 20/200 or worse, OR your visual field is 20 degrees or less. I qualify on the field side. My field is well under 20 degrees. I’ve been legally blind for years.

But the technician saw 20/25 on my chart and couldn’t process it. How can someone who reads 20/25 be legally blind? She didn’t know the field criteria existed. And this was in a retina specialist’s office. Not a general practice. Not a walk-in clinic. A retina specialist.

I had to go back. Multiple visits. Each time explaining the same thing. Each time being told they’d “look into it.” Each time leaving without the form. Finally, I was in the office and forced them to talk to the doctor about it while I was sitting right there. He told her – yes, the field qualifies. Fill out the form. It took him thirty seconds to confirm what I’d been saying for a year.

One year. For a piece of paper that acknowledges what I live every day.

You Can’t Even Get Your Own Numbers

Here’s something that shouldn’t surprise me but still does. I don’t know my exact per-eye acuity. Not because I haven’t been tested – because they don’t tell me. They don’t put it on the papers I take home. They don’t include it in the visit summary. They write it in my chart, behind a system I can barely access, and move on.

I know my left eye is sharper. I know my right is closer to 20/40. I know both together test somewhere around 20/25 – but honestly, I’m not even sure of that. Is that for distance? For close up? Nobody wrote it down clearly enough for me to tell you. I’m writing an essay about a number I can’t even verify. Let that sink in. Sounds great – except that 20/25 comes with flashing lights across my vision, fogging that rolls in and out, glare that washes out everything, and a center that falls apart the moment the lights go down. But hey – 20/25. You’re not blind.

I had to piece that together myself from fragments of conversations and half-remembered readouts. My genetic test report? I have every letter of it – because I requested it myself. My audiogram? I have the graph – because I took a picture of the screen before they closed it. My acuity numbers by eye? I have to ask. And every time I do, I get the same look – a pause, a glance at the screen, “hmm, let me see what we have in the chart.” Like nobody’s ever asked before. Like my own numbers are a surprise request. Meanwhile, that same data – my data – gets stripped of my name and sold to the highest bidder. They can profit from it. I can’t even get a clean copy.

The system collects data about me all day long. It measures my eyes, maps my field, scans my retina, tests my pressure. It builds a detailed picture of my vision. And then it puts that picture in a folder I can’t see and hands me a checkout sheet that says “follow up in 6 months.”

I’m an engineer. I make decisions based on data. You’d think the medical system would want its patients to have their own data. You’d be wrong.

The Forms Don’t Have a Box

Here’s why this matters beyond one frustrated patient.

Every medical form, every insurance screen, every disability checklist starts with acuity. “What is your best corrected visual acuity?” You write 20/25. The system sees that and thinks: this person can see. Check. Move on.

There’s no box for “can read the chart but can’t see the room.”

There’s no box for “legally blind by visual field with near-perfect central acuity.”

There’s no follow-up question: “What is your visual field?” On most forms, it doesn’t exist. The entire intake system is designed around a single number that measures the one thing we still have.

Insurance denials. Accommodation requests. Disability applications. Parking placards. Tax documentation. All of them start with acuity. All of them see 20/25 and stop reading.

What 10 Degrees Actually Looks Like

People hear “legally blind” and they picture darkness. That’s not what this is.

I can read a text message. I can see your face – if it’s directly in front of me and I’m close enough. I can read a menu. In most cases of RP, the center still works – it’s the last part the disease touches. Mine is decent, though other problems like keratoconus blur it more than RP alone would.

But here’s what 10 degrees means in objects you already know. Hold a post-it note at arm’s length. That’s roughly the center – the part I can actually read and make sense of. Around it, the view starts to fade – and in that fading zone, my brain is still trying to do what it used to do with full vision: catch motion, recognize shapes, build a picture of the room. But the light-sensing cells (photoreceptors) thin out the further you get from center – more and more dead as you reach the edge of my 10 degrees – so the brain is running on less signal, more guesses, and memory. I can see about six inches across, but I can only read or make out detail in the inner three. Everything outside that is gone. Not dark. Gone. A credit card barely fits in the center. A smartphone? I have to scan it top to bottom. A full page? Forget it – I’m reading it one post-it-sized piece at a time.

Now step back. At conversation distance – about five feet – 10 degrees gives me a face. That’s it. Your face. Not your hands. Not what you’re holding. Not the person standing next to you. Just a face, floating in nothing. At ten feet across a room? Head and shoulders. At twenty feet in a parking lot? Waist to head – if I’m looking right at you. Wave at me from across the room and I will never see it.

And here’s something people don’t expect. Sometimes I step BACK from something to see it better. Sighted people lean in. I back up. At two feet, 10 degrees gives me a post-it note. At four feet, it gives me a dinner plate. I doubled what I can see by stepping away. Then once I spot what I need, I step back in to read the detail. Every moment is a zoom decision – see more, or see sharper. You can’t have both at the same time. Sighted people never think about this because they get both for free. I had both once too.

Drop something on a dark floor and the math gets worse. A dime is less than an inch wide. My window at arm’s length is about three inches. That’s not a glance – that’s a search operation. Grid by grid. Square by square. Five minutes to find what a sighted person spots in a second.

Everything outside that post-it note is gone. And the medical system says 20/25.

The Tax Break That Costs More Than It Saves

Once I finally got that legal blindness form, I learned something. The tax deduction for legal blindness is roughly the same as a dental write-off. Barely noticeable on a return.

But the doctor visits required to maintain that documentation? Thousands of dollars a year. I wait two to three hours per visit. I pay out of pocket for most of it. My insurance covers almost nothing for retina specialists. And I have to go back regularly to keep the paperwork current.

You pay more to prove you’re blind than the system gives you back for being blind. That’s the math. Nobody talks about it because nobody with 20/25 is supposed to be in this conversation.

The Broken Equipment

I mentioned the visual field test – the one that maps peripheral vision. It should be the gold standard for RP patients. But in my experience, the machines are often the oldest equipment in the office.

I sat in that dome multiple times over the years. I could hear the mechanisms moving. And as an engineer who’s spent a career listening to machines, I knew something was off. The light would stutter. The positioning would skip. I’d tell them – this isn’t working right. They’d run it anyway.

And even when the machine works, the test itself is flawed. They flash a bright, wide light at your peripheral vision and ask “do you see it?” Yeah, I see it. It’s a bright light in a dark dome. But that’s not how real life works. In real life, things at the edge of your vision are dim, small, and moving. A person walking up beside you. A car pulling out from the left. A step below your line of sight. The test uses a stimulus so strong that you can catch it early in the disease even as your real-world peripheral vision is already failing. The test says you’re fine. You’re not fine – the test just isn’t asking the right question.

The test would come back and say I was fine. I wasn’t fine. But the printout said so, and the printout is what goes in the chart.

When I finally got to a doctor with modern equipment, the results matched what I’d been living for years. Not fine. Not even close. The difference wasn’t my eyes – it was the machine. And nobody listened when I told them.

That’s the other part of this. The test that actually matters for us is the one that gets the oldest equipment, the least attention, and the most skepticism when a patient says it isn’t working.

The Workplace Version

At work, I’m productive. I’m a principal-level cloud architect. My boss is the best I’ve ever had – she’s never seen this get in the way of my work. If anything, she counts on me more because of what I bring, and she’s never once made me feel like I need to be helped. She fights for me and she knows what I can do. If she ever reads this, I need her to know that. But one good boss doesn’t fix a broken system.

I need a monitor that’s bright enough and sharp enough for my eyes to work – that costs four or five times what the standard budget allows. I didn’t tell HR for years. Last year I finally let them know – not even asking for help, just disclosing it. Nothing came back. No follow-up. No “what do you need?” Just silence. I need help with lighting. With screen contrast. With knowing when someone walks into my workspace. With not falling down stairs I can’t see. And hearing aids? Not covered. The two things I need most to do my job – see the screen and hear the meeting – I pay for myself.

And here’s the part nobody says out loud. I have to be careful how hard I push. Because if the system actually saw me – really saw what I need – I’d be expensive. And the question every disabled worker carries in the back of their mind is: who wants to hire someone who’s deaf and going blind? You fight to be recognized. But you’re afraid of what happens when you are.

But the form says 20/25. And 20/25 means “fine.”

They’re Not Measuring My Eyes

Here’s what I keep coming back to. That 20/25 isn’t a measurement of my eyes. It’s a measurement of my brain and whatever hardware is strapped to my face – glasses, contacts, specialty lenses – all stacked together.

And the system always uses the best number it can find – both eyes together, best correction applied. They don’t track what each eye sees on its own or what happens without the lenses. Real numbers cost time and money. So they write down the best one and move on.

If you’re a doctor reading this, I know that might sting at first. Sit with it for a second. Am I wrong?

My brain takes two imperfect, distorted signals – one from a cornea that’s coned out of shape, one that’s slightly better – and fuses them in real time into something sharper than either one alone. It does this automatically. I don’t feel it. I don’t think about it. It just happens. Every second of every day, my brain is running a compensation algorithm that no doctor measures and no form captures.

And it goes further than that. My brain is also filling in the gaps around that 10-degree center. In familiar places, it uses memory to build a model of the room so I feel like I see more than I do. It’s predicting where objects are. It’s guessing what’s in my peripheral based on what was there last time I looked. It’s working overtime to make my world feel complete – and it mostly succeeds, until it doesn’t. Until I walk into something. Until I miss someone waving. Until I trip on a step I didn’t see.

And here’s the thing – writing this essay is what made me see it. My brain started reverse-engineering itself, and somewhere between the post-it note and the paper towel roll, I realized I was writing my second research hypothesis about how RP vision actually works. These brain cells – the ones I hope don’t die like my photoreceptors – apparently have opinions.

All of that processing costs energy. By mid-afternoon I’m drained – not from what I did, but from what my brain did FOR me without asking. The system doesn’t measure that. There’s no test for “how hard is your brain working to keep you functional.” There’s no billing code for cognitive compensation. There’s just 20/25 on the chart and a technician who thinks I’m fine.

The Label Problem

I have a learning disability too. Not the kind where you can’t learn – the kind where you can’t get what you’ve learned out onto paper. My brain processes fast. My logic scores test in the top percentile. But written output? That’s where it breaks.

It’s the same pattern. “Learning disability” measures the output and calls the whole person disabled. “Legally blind with 20/25” measures the center and calls the whole person sighted. And “lazy eye” – the label they gave my right eye – means “we don’t know why it’s weaker.” Three labels that describe a symptom and pretend it’s an explanation.

Both vision and learning – the system looks at one number, draws a conclusion about the entire person, and files them away. Both miss the actual problem. And both force us to spend years explaining what the number doesn’t capture.

I’m not getting dumber – my desk is shrinking. Same brain, less room to work with. The acuity chart doesn’t measure the size of my desk. It measures the sharpness of my pencil. And the pencil is fine. The desk is almost gone.

What Should Change

This isn’t complicated. Four things would fix most of it.

Put visual field on the intake form. Right next to acuity. Two numbers instead of one. “Best corrected acuity: . Visual field (degrees): .” That’s it. One extra line. Every RP patient, every glaucoma patient, every stroke patient with visual field loss would benefit. The data already exists in the chart – it just doesn’t make it onto the forms that matter.

Train the front office. The technician who didn’t know what 20/200 means works in a retina specialist’s office. If the front-line staff in a retinal practice don’t understand field-based blindness, what chance does a patient have at a general practice? A ten-minute training session would fix this. Nobody’s done it.

Track the real numbers. Not just the best corrected, both-eyes-together result. Track each eye on its own. Track uncorrected vision. Track the visual field. Track the scans. Give patients their own data – clearly, every visit, without having to ask. The full picture costs a few extra minutes. Not having it costs us years of fighting a system that only sees one number.

Stop using acuity as a gate. Insurance forms, disability applications, accommodation requests – stop making acuity the first and only filter. If someone qualifies as legally blind by visual field, the system should recognize that without requiring us to fight for it for a year.

The eye chart is a useful test. It measures what it measures. But it was never designed to capture what RP takes from us. Using it as the only measure of vision is like judging how well you can hear by testing only one ear. In a quiet room. With no background noise. And then telling you you’re fine.

The eye chart measures the one thing we still have and misses everything we’ve lost. That’s not a medical problem. That’s a design problem. And I’m an engineer. I notice design problems.

Five years ago, if you had Usher syndrome or retinitis pigmentosa and asked about treatment, the answer was simple: there isn’t one. Luxturna existed for a tiny fraction of RP patients – RP being a genetic disease that slowly kills the light-sensing cells in your retina – those with RPE65 mutations, less than 5% of cases – and for everyone else, the conversation was short. Wear sunglasses. Take vitamin A. Wait.

That answer is no longer true. Well – the sunglasses part is still good advice for everyone.

Today, there are more than 50 therapies under active investigation for inherited retinal diseases alone. Gene therapy. Stem cells. CRISPR gene editing. Optogenetic proteins that turn surviving cells into substitute photoreceptors. An oral pill that slows vision loss – just a pill, twice a day, no surgery. Some of these are in Phase 3 trials (the final stage of testing before FDA approval – Phase 1 checks safety, Phase 2 checks if it works, Phase 3 proves it at scale). Some are filing for FDA approval right now.

I’m writing this from inside the Usher syndrome and retinitis pigmentosa world, because that’s what I live with. But the problem I’m about to describe isn’t unique to my condition. If you or someone you love is facing any disease with clinical trials and nobody to help you navigate them – this is your story too.

Whether you have Usher syndrome – Type 1, 2, or 3 – or non-syndromic retinitis pigmentosa, the same retina is degenerating, the same light-detecting cells in your retina (photoreceptors) are dying, and many of the same therapies could help. RP without hearing loss affects roughly 1 in 4,000 people – potentially millions worldwide. Usher syndrome affects over 400,000. Together, we are a large community facing the same set of questions.

The science has exploded. But something hasn’t kept up.

Nobody is helping patients think about what to do with all of this.

One important note: I dated this essay February 2026 for a reason. This landscape moves fast. A trial recruiting today could be full tomorrow. A therapy approaching FDA approval could fail next month. What I’ve written here is a snapshot – accurate as of when I researched it, but not permanent. If you’re reading this months or years later, verify everything. The questions I’m raising don’t expire, but the specific answers do.

The Menu Nobody Explains

Here’s what’s actually out there, simplified. Not a list of every trial – just the categories, so you understand what’s on the table.

Gene therapy delivers a working copy of your broken gene directly into the retina. If it works, one injection could be a permanent fix. But here’s the catch: the delivery vehicle – a tiny virus called AAV – can only carry a gene up to about 4.7 kilobases (units of DNA length) in size. Some genes fit. Some don’t. Your genetic diagnosis determines whether gene therapy is even possible for you today.

Exon skipping is the next approach – and to understand it, you need to know that a gene is made up of sections called exons (think of them as chapters in an instruction manual). If one chapter is damaged, exon-skipping therapy tells the cell to skip that chapter and read the rest, producing a shorter but partially functional protein. The medical name for these therapies is antisense oligonucleotides (ASOs). They require repeated injections. Right now, the only ASO in trials for USH2A targets exon 13 – one specific chapter. But new research is pushing further – researchers have demonstrated multi-exon skipping in zebrafish for different parts of the USH2A gene, which means the approach could eventually reach patients whose mutations are in other chapters.

Cas13 RNA editing is an emerging approach worth knowing about. Instead of cutting DNA like CRISPR, it edits the RNA message – the working copy your cell makes from the DNA blueprint – correcting errors without permanently altering your genome. Early lab work has shown promising efficiency for USH2A, but it’s still in the early stages.

Neuroprotection takes a completely different approach. Instead of fixing the gene, it protects the cells you still have. Your rods (the cells that handle night vision and peripheral vision) die first – that’s the genetic part. But your cones (the cells that handle central vision and color) die second, from oxidative stress – basically, they’re drowning in oxygen that the rods used to consume. A neuroprotective drug fights that oxidative damage. It doesn’t fix the cause, but it slows the collapse.

Optogenetics is the most radical idea. When your photoreceptors are gone – rods, cones, all of them – there are still other cells in the retina. Optogenetic therapy delivers a synthetic light-sensitive protein to those surviving cells, essentially turning them into substitute photoreceptors. This works even in advanced disease, when other therapies can’t help.

Cone reactivation is a new approach that sits between neuroprotection and optogenetics. Some cones in advanced RP aren’t dead – they’re dormant. They still have their light-sensing proteins but they’ve gone silent. This therapy delivers a gene that wakes them up. The first patient was treated in October 2025. If it works, it could offer better vision than optogenetics because the cells being reactivated are real cones, not repurposed cells. (Added Feb 17, 2026 – SparingVision NYRVANA trial)

Cell replacement is exactly what it sounds like. Lab-grown photoreceptors injected into the retina to replace the ones you’ve lost. This is the earliest-stage approach, but it’s real – the first patients were treated in 2025.

That’s the menu. Seven fundamentally different approaches, each with different trade-offs. And the first thing you should notice is that most of them don’t require knowing your gene at all.

Why Some People Have Options and Others Don’t

This is where it gets unfair.

If you have RP caused by RPGR mutations – the most common form of X-linked RP – your gene is about 3.5 kilobases (a measure of gene size – think of it like file size for DNA). It fits in one AAV (a harmless virus used as a delivery vehicle to carry the corrected gene into your cells) easily. Multiple gene therapy trials are running, including a Phase 2/3 trial with data expected later this year.

If you have Usher Type 1B, caused by mutations in MYO7A, your gene is about 6.6 kilobases – too big for a single AAV, but researchers figured out how to split it across two. Dual-AAV gene therapy. The trial (LUCE-1) has completed enrollment – 15 adults dosed – and they’re now collecting safety data. That’s real progress for a gene that was considered untreatable not long ago.

If you have RP caused by PDE6B mutations, there’s a gene therapy in trials with positive two-year data. CNGA1 mutations – a novel AAV approach is testing increasing doses. Even PRPF31, which causes a form of autosomal-dominant RP (meaning one broken copy of the gene is enough to cause it, unlike most RP which needs two), has an RNA therapy (a treatment that works at the instruction level of the gene, rather than replacing the whole gene) in Phase 2/3.

But if you have Usher Type 2A – the most common form, affecting roughly half of all Usher syndrome patients worldwide – your gene, USH2A, is 15.6 kilobases. That’s more than three times too big for AAV. It doesn’t fit in one vector. It doesn’t even fit in two. The standard delivery truck can’t carry it.

And USH2A isn’t alone. The EYS gene, responsible for another common form of RP, is about 9.5 kilobases – also too big, also with no gene therapy trials. If you lost the genetic lottery with a large gene, you’re in the same position.

Let that sink in. The most common form of Usher syndrome has the hardest gene to treat. And it’s not even close. I learned this about my own gene sitting at my desk one afternoon. Nobody had ever told me.

And it goes deeper than just the gene. Two people can both have USH2A and be on completely different paths. It depends on what’s actually broken. Think of it like two cars that won’t start. One has a bad spark plug – the part is there but it’s not firing right. That’s like having one letter changed in the DNA code (a missense mutation) – the gene is all there, it just has a typo. Therapies like base editing might be able to fix that typo directly. The other car has a cracked engine block – you’re not swapping parts, you need a different plan entirely. That’s like my situation. One of my USH2A mutations is a whole section deleted (exons 22-24 – gone, not there). You can’t edit what’s missing. Same gene. Different break. Different fix. That’s why “USH2A gene therapy” isn’t one conversation – it’s a dozen different conversations depending on what exactly went wrong in your copy.

But here’s something that works in our favor: not all mutations are equally rare. One specific USH2A mutation – c.2299del – accounts for 20 to 25 percent of all disease-causing USH2A variants. One in four or five. That means it’s the most studied, the most well-characterized, and the most likely to be targeted first when mutation-specific treatments arrive. If your genetic report shows that variant, you’re not alone in the dark – you’re in the largest group of USH2A patients there is. (Added Feb 17, 2026)

The only gene-specific option for USH2A right now is an ASO that skips exon 13 – and that only helps patients whose mutations happen to be in exon 13. But the science is moving. Researchers have proven multi-exon skipping works in zebrafish for exons 30-31 and 39-40, and Tim Yu – the researcher who created milasen, the first personalized ASO – is developing new USH2A ASOs through the PUSH initiative. The approach could eventually scale to cover different mutations across the gene. That’s not here yet, but it’s not theoretical either.

If your mutations are somewhere else in that massive gene, there is no gene-specific therapy in trials today. The CRISPR approach for USH2A – EDIT-102 – is dead. Editas quit retinal disease entirely in January 2023, cut 20% of staff, and pivoted to other conditions. The program is still orphaned – no partner has picked it up, no IND has been filed, and there is no clinical timeline. I’m not sugarcoating that. It’s a real setback. (Verified Feb 17, 2026 – confirmed still dead)

This is why gene-independent therapies matter so much. The neuroprotective pill doesn’t care what gene you have. Optogenetics doesn’t care. Cell replacement doesn’t care. For USH2A patients, EYS patients, and anyone else with a gene that doesn’t fit in an AAV vector, these gene-agnostic approaches aren’t a fallback plan. They’re the primary hope.

The Real Risks Nobody Talks About

Before I talk about risk, I want to be clear: real progress is happening. An oral neuroprotective pill showed over 50% reduction in photoreceptor loss in a two-year trial – though the primary endpoint didn’t reach statistical significance, the trend was strong enough for the FDA to grant it Breakthrough Therapy status. (Updated Feb 17, 2026 – Nacuity Phase 1/2 results) Optogenetic therapy has shown sustained vision gains after a single injection. Three therapies are approaching FDA approval right now. This is not false hope – this is science delivering results.

But hope without information is dangerous. And there are three layers of risk that nobody is explaining clearly.

The first risk is physical. Trials can make you worse. This isn’t theoretical. In a recent gene therapy trial for PDE6A mutations, two out of nine patients experienced severe vision loss. A major Phase 3 gene therapy trial for RPGR – backed by Johnson & Johnson – failed its primary endpoint in May 2025. These are not rare complications buried in fine print. These are real outcomes that happened to real people who volunteered for science.

Trials are not “free treatment.” They are experiments. The earlier the phase, the less is known about safety. You are helping researchers learn – and that is valuable – but you need to understand what you’re risking.

The second risk is strategic. When you receive an AAV-based gene therapy – an injection into your eye – your immune system produces defense fighters called antibodies against that viral vector. Those antibodies can reduce the effectiveness of a second gene therapy. You may have just used your one shot, and it might affect your eligibility for something better that comes along in three years.

Nobody explains this to patients in strategic terms. In clinical trial language, being untreated is called “treatment-naive.” The word makes it sound like you don’t know any better. The reality is nobody offered you anything.

But that status is actually a strategic advantage. If you take a pill first – a pill that shields your remaining light-sensing cells from dying (a neuroprotectant), requires no surgery, and, based on what we know today, doesn’t create the antibodies that could complicate future gene therapy – you’ve likely preserved your future options. Gene therapy can still come later. The pill is unlikely to close doors that an injection might.

An important reality check: As of early 2026, that neuroprotective pill is not something you can walk into a doctor’s office and get. NPI-001 completed Phase 1/2 and has a confirmatory trial planned, but it hasn’t started yet. The NAC Attack trial at Johns Hopkins is enrolling – 485 patients across 31 sites – but it’s still a trial, not a prescription. Over-the-counter N-acetylcysteine supplements exist, but they’re not the same clinical-grade formulation and nobody knows if they work the same way. The strategy is sound. The access isn’t there yet. I’m in the same position you are – I can see the logic, and I can’t get the pill either.

This isn’t obscure science. The AAV antibody problem is well-documented in medical journals. The strategic implication – that treatment ORDER matters, that a pill before an injection might be the smarter sequence – is obvious once you see it. But nobody is telling patients.

The third risk is timing. You’re always losing. The question is whether what you have left right now is enough to wait for something better, or whether the clock is forcing your hand.

If you still have central vision worth protecting – and vision loss is a spectrum, so only you know where you are on it – jumping into an early-phase gene therapy could mean risking what you have AND generating antibodies that block the next therapy. Based on what we know today, that’s a double hit that may be very difficult to undo.

But if your vision is advanced-stage – very narrow field, struggling daily – the calculus shifts. You have less to risk and less time to wait. Earlier-phase trials may make more sense. Optogenetics was designed specifically for people who have already lost most of their photoreceptors.

Where you are in the progression changes everything. And nobody is helping you figure out where that line is for YOUR situation.

And if you’re a parent making this decision for a child, it’s even harder. A mother recently told me she’s been dragging her 17-year-old son to professors all over Poland – each one says something different, and the last one told her flat out there’s nothing. Another parent pointed out that acting too early with one therapy could trigger an immune response that limits what you can do later – but waiting too long means losing the cells a better therapy would need. Parents are being asked to sequence treatments for their kids with no framework and no guidance. That’s not a gap. That’s a cliff.

But What About Placebo?

One question that comes up a lot – and it’s a fair one – is: what if I join a trial and just get the placebo?

Here’s what happens in most cases. At the end of the trial, they “unblind” – they tell you which group you were in. If you got the placebo and the therapy worked, most trials offer what’s called an open-label extension, which means the placebo group gets access to the real treatment. You’re not abandoned.

And increasingly, newer eye trials avoid the placebo problem entirely. They treat one eye and use your other eye as the control. No placebo. No guessing.

A few other things worth knowing: being in one trial doesn’t block you from joining another later (though you may need a washout period between them). And regardless of which arm you’re in – treatment, placebo, even if the trial fails – the Foundation Fighting Blindness considers trial participants “pioneers.” You contributed to the science. That data matters whether the therapy worked for you personally or not.

The placebo fear is understandable. But it shouldn’t be the thing that keeps you from considering a trial.

The Clock

While you’re weighing these decisions, your retina isn’t waiting.

Retinitis pigmentosa is measurable. A layer on your retinal scan that shows where you still have intact light-sensing cells – doctors call it the ellipsoid zone – shrinks over time. How fast depends on your gene, your mutations, your age – one large study of USH2A patients measured it at roughly 107 micrometers per year (about the width of a single human hair – lost every year), but the rate varies widely across different types of RP. What doesn’t vary is the direction. Every year, the ring of surviving photoreceptors gets smaller. Every year, there are fewer cells left to save.

You’re always losing. It never stops. It never stabilizes. I think about this every time I notice something I could see last year that I can’t see now.

Most gene therapies and neuroprotective treatments require that you still have photoreceptors to rescue. If you wait too long, you pass a point where the cells are gone and those therapies have nothing to save. Animal studies suggest that treating too late significantly reduces or eliminates the benefit.

The exceptions – optogenetics and cell replacement – are designed to work even after photoreceptors are gone. Early results suggest they don’t need your original cells to provide benefit. That’s why they matter so much for people further along in the progression.

But here’s the tension nobody talks about honestly: waiting for a better therapy might mean losing the cells that therapy needs to work. Acting now might mean closing the door on something more effective coming in two years. Every patient lives in this tension, and the right answer is different for everyone. There are no fixed rules. No two patients progress the same way. You’ll make this decision without complete information – and nobody can tell you if you got it right. That uncertainty is one of the hardest parts of living with this.

The Doctor Problem

Here’s what makes all of this worse: most patients can’t get help navigating it even if they want to.

I don’t know which doctor I’m supposed to see for this. A retinal specialist? Mine told me “there’s nothing out there” – which was factually wrong. A genetic counselor? They interpret your mutations but don’t track the treatment landscape. A low-vision specialist? They help you cope with what you have, not plan for what’s coming. Your primary care doctor? They’ve probably never heard of Usher syndrome. I’m still not sure which one I’m supposed to call.

After months of building context with AI tools, I found four active clinical trials I likely qualify for – trials no doctor had ever mentioned. Not through a genetic counselor. Not through a patient organization. I used an AI assistant – and I need to be very clear about what that means.

Through that work, I learned more about my treatment options than I had in fourteen years since my diagnosis. I described my genetic mutations, my visual field, my acuity, and asked: what’s out there for me?

This isn’t a criticism of doctors. It’s a structural problem. Doctors have limited time, and their patients have hundreds of conditions. They focus on the ones they see most – which makes sense for them but fails anyone with something rare. The rarer your condition, the wider the gap. And Usher syndrome, at 1 in 10,000 to 1 in 25,000, is very rare. Your retinal specialist might see one or two USH patients a year. They can’t track the trial landscape for every rare condition they encounter. “Nothing’s out there” isn’t malice – it’s the default answer that takes zero research time for a condition that represents a fraction of their practice. And even if they wanted to dig deeper – there’s no billing code for it. Insurance pays doctors for visits and procedures, not for spending a hundred hours researching one patient’s rare condition. The system doesn’t allow it. That’s why I learned to do it myself – and why I’m writing this essay, so you at least know what questions to bring to the conversation.

And it gets worse. Even if a doctor wanted to help you navigate the treatment landscape, they don’t have the tools. There is no system in any hospital or clinic that takes a patient’s genetic profile, cross-references it against active trials, weighs the strategic implications of treatment order, and produces a personalized roadmap. That tool doesn’t exist. Not in the biggest research hospitals. Not in the most funded medical centers. With all the money in the healthcare system, nobody has built it.

The result is that patients like me are on their own. I’m doing what a specialist should be doing for me – reading trial databases, understanding eligibility criteria, thinking about which therapy to pursue, and in what order. I’m doing it because nobody else will. And the system that tells me “don’t self-diagnose” is the same system that offers me nothing in return.

And I have an engineering background, decades of technical experience, and access to AI tools. What about the patient who doesn’t?

A Word About AI (Read This Carefully)

I want to be direct about the AI part, because I don’t want anyone to read this essay and do something dangerous.

When I say I used AI to research my treatment options, I am not saying I opened a free chatbot and asked “what clinical trial should I join?” That would be reckless, and the results would be unreliable.

Here’s what I actually did:

I use a paid, top-tier AI model – not a free chatbot. I pay for the most capable plan available because the quality of the reasoning matters when you’re dealing with medical decisions. I fed it my full genetic test report, my audiogram, my medical history, my visual field measurements. I built context over hundreds of hours of conversation – not one quick question.

And critically: I verified everything. AI gets things wrong. It can hallucinate trial names, invent eligibility criteria, confuse one therapy with another. I caught errors and corrected them. I cross-checked every claim against ClinicalTrials.gov, published research, and organization websites. When the AI said something I couldn’t verify, I threw it out.

This is a skill, not a shortcut. I have 39 years of engineering experience that taught me how to evaluate technical information critically. Even with all of that, what I find may not be 100% right. The treatment landscape changes weekly. A trial that was enrolling yesterday may have stopped today.

Please do not read this essay and go ask a free AI chatbot what trial you should join. The information you get may be outdated, incorrect, or completely fabricated. On top of that, most AI models – free or paid – only know what existed when they were trained, and that data is typically six months to a year old. In a landscape where trials open and close every week, the AI might confidently tell you about a trial that’s already full, failed, or never existed. AI is a powerful research tool – but only if you bring deep context, verify everything, and understand its limitations.

What I found through months of careful research was more than my doctors had told me in fourteen years. That’s real. But I didn’t find it by typing a question into a chat box. I found it by doing the hard work that someone in the medical system should be doing for patients like us.

The Hearing Side (A Stark Contrast)

I have Usher syndrome, which means I’m losing both vision and hearing. Everything I’ve written above is about the vision side – and the vision side has over 50 active trials. Three therapies are approaching FDA approval right now.

The hearing side? As of February 2026, there are exactly four legitimate clinical trials for genetic hearing loss. All four target a single gene – OTOF – which causes auditory neuropathy, not Usher syndrome. For Usher syndrome hearing loss – any type, not just mine – there are zero trials. Not one. Not even preclinical. And the OTOF trials can’t help us – they fix a signaling problem in otherwise healthy hair cells. Usher syndrome damages the hair cells themselves. It’s a different problem entirely. I’ve had hearing loss since birth. Fifty trials for my eyes. Zero for my ears. And for those with Usher Type 1 who also deal with balance problems – there’s nothing on that front either. No trials, no drugs, no gene therapy. But here’s the thing – physical therapy actually helps. Balance training and vestibular rehab can make a real difference for people with Type 1, especially kids. The problem is the same one we keep running into: nobody tells parents it exists. One Coalition ambassador with Type 1 told me she wishes her childhood doctor had listened when her mom asked about PT. By the time she found it on her own, she’d already spent years struggling with something that could have been managed. The tools exist. The referrals don’t. I’m not sure what to do with any of that.

The USH2A gene is too big for AAV delivery to the ear, just like it’s too big for the eye. But while vision researchers have found creative workarounds – gene-agnostic approaches, neuroprotection, optogenetics – nobody has done the same for hearing. The cochlear damage in Usher syndrome happens during development, and by adulthood, it may be structural damage that gene therapy can’t reverse.

There is one small sign of progress. In 2025, Save Sight Now achieved the first hearing rescue in a MYO7A mouse model – proving that gene therapy can reach beyond vision to hearing, at least in the lab. It’s a mouse, not a human, and it’s one gene, not all of Usher. But it’s the first time anyone has demonstrated hearing rescue in an Usher model. That matters.

Meanwhile, the hearing treatment space is flooded with false hope. Hair cell regeneration therapies that showed zero benefit in Phase 2 trials. Companies that raised millions and then dissolved. Stem cell clinics charging 5,000𝑡𝑜30,000 for unproven treatments. Supplements marketed as hearing restoration with no clinical evidence.

For now, hearing aids and eventually cochlear implants remain the only proven interventions for Usher syndrome hearing loss. I mention this not to be discouraging, but because honesty matters more than hope. The vision landscape is genuinely exciting. The hearing landscape is not there yet. Knowing the difference protects you from spending money and hope on things that don’t work.

What Should Exist

Two things are missing that should be straightforward to build.

A framework for thinking about your options. Not medical advice. Not “do this.” A set of questions: Given your gene, your specific mutation, where you are in the progression, your age, and what’s available – here’s what to ask your doctor. Here’s what to look up before you enroll in anything.

Someone in the medical system who thinks about this from the patient’s side. Right now, researchers think about their trial. Doctors think about their specialty. Organizations think about enrollment. Nobody is thinking about the patient sitting in the middle of it all, trying to figure out which door to walk through when every door might close others behind it.

Why I Wrote This

I’m not a doctor. I’m an engineer with Usher syndrome who built his own research tools because nobody else would do this work for him. That fact alone tells you something is broken.

This essay is the beginning of filling that gap. Not with answers – with the right questions. Because once you know what to ask, you can start finding your own answers. And if your doctor can’t help you navigate it, at least now you know what to navigate.

I wrote this about Usher syndrome and RP because that’s what I live with. But this gap exists across every disease where clinical trials are the path to treatment. If you’re facing it in your world, the same questions apply. Which trial first? What am I giving up? Who’s helping me decide?

Five years ago, there was nothing. Today, there are over 50 trials and three therapies approaching approval. The gap is real – but so is the progress. We are closer than we have ever been. No one should have to navigate this alone.

Where Things Stand: February 2026

The treatment landscape changes fast. Below is a snapshot of what’s active or approaching approval as of this writing. Verify current status before making any decisions.

Approaching FDA Approval

Therapy Company Type For Whom Status MCO-010 Nanoscope Optogenetic Advanced RP, any gene Rolling BLA, 3-year durability data OCU-400 Ocugen Gene-agnostic gene therapy Any RP BLA submission H1 2026 + Expanded Access granted (Updated)DB-OTO Regeneron Hearing gene therapy OTOF hearing loss only (not USH) NEJM published: 11/12 improved, 3 normal hearing

Phase 3 / Late-Stage Trials

Therapy Company Type For Whom Status NPI-001 (NACA) Nacuity Oral pill (neuroprotection) All USH/RP Breakthrough Therapy; Phase 3 planned 2026 (Updated)NAC Attack Johns Hopkins/NEI Oral pill (neuroprotection) All RP 485 patients, 31 sites – largest RP trial ever (Updated)Laru-zova Beacon Gene therapy RPGR/X-linked RP Phase 2/3 fully enrolled, positive 9-month interim (Updated)

Phase 1-2 Trials (Selected)

Therapy Company Type For Whom Status AAVB-081 (LUCE-1) AAVantgarde Dual-AAV gene therapy USH1B (MYO7A) Enrollment complete, 15 adults Ultevursen (LUNA) Sepul Bio ASO exon skipping USH2A exon 13 only (~16,000 patients worldwide) Phase 2b, 81 patients enrolling (Updated)SPVN06 SparingVision Cone preservation All RP (gene-agnostic) Dosing COMPLETE Feb 2026; pivotal trial 2027 (Updated)SPVN20 (NYRVANA) SparingVision Cone reactivationAdvanced RP (gene-agnostic) NEW – first patient Oct 2025 (Added)jCell jCyte Retinal progenitor cells All RP (gene-agnostic) Phase 2b, Q1 2026 interim results expected OpCT-001 BlueRock/Bayer iPSC cell replacement Advanced RP Fast Track + Orphan Drug (Jan 2026)(Updated)HORA-PDE6b eyeDNA Gene therapy PDE6B mutations Positive 24-month data; seeking accelerated path (Updated)BF844 Usher III Initiative Small molecule (oral) USH Type 3 (CLRN1) Phase 1 complete, bridge to Phase 2 ZVS203e ZVS Bio CRISPR gene editing RHO mutations (first CRISPR for RP) Phase 1 dosing ZM-02 Zhongmou Optogenetic Advanced RP, any gene 52-week data: color perception recovered; US IND cleared (Updated)KIO-301 Kiora Molecular photoswitch Advanced RP, any gene Phase 2 ABACUS-2 enrolling; $400M+ partnership (Updated)

The Big Picture

Category Active Trials Closest to Patients Gene-specific vision 22+ Laru-zova (RPGR), ultevursen (USH2A exon 13) Gene-independent vision 18+ MCO-010, OCU-400, NPI-001, SPVN06, SPVN20 Hearing (all genes) 4 DB-OTO (OTOF only) Hearing for USH 0 Nothing

Questions From the Community

This essay generated something I didn’t expect. Within days of posting it, questions started coming in – from the USH Blue Book, Facebook, LinkedIn, and private emails. A lot. From the US, Poland, Russia, Czech Republic, France, Italy, UK, Canada, Australia. All asking the same kinds of questions. All saying the same thing: nobody ever explained this to me.

That’s the guidance gap in real time. Here are some of the questions that came up most, with short answers based on what I’ve found. These are not medical advice – they’re one patient’s research. Verify everything with your own doctors and at ClinicalTrials.gov.

“What’s out there for USH2A specifically?”

Leo M. (London, UK) – brother has USH2A | Dan C. – daughter, 23, USH2A | Marzena G. (Poland) – son, 17, USH2A

The honest answer: less than we’d like. The USH2A gene is 15.6 kilobases – more than three times too big for standard gene therapy delivery. The only gene-specific option in trials right now is an ASO (exon-skipping therapy) that targets exon 13 – and that only helps if your mutation is in exon 13. But the gene-independent therapies – the neuroprotective pill, optogenetics, cone preservation, cell replacement – don’t care what gene you have. Those are the primary hope for USH2A right now. And the science is moving: multi-exon skipping has been demonstrated in the lab, and new ASOs are being developed through the PUSH Initiative.

“What if I join a trial and just get the placebo?”

Peter D. (Facebook)

Fair question. At the end of the trial, they unblind – they tell you which group you were in. If you got the placebo and the therapy worked, most trials offer what’s called an open-label extension: the placebo group gets access to the real treatment. You’re not abandoned. And increasingly, newer eye trials avoid the placebo problem entirely – they treat one eye and use your other eye as the control. No placebo. No guessing. Being in one trial also doesn’t block you from joining another later.

“The decision isn’t just gene-level – it’s mutation-level.”

Anna R. (Czech Republic) – son has USH1D

She’s right, and her point made the essay better. Two people with the same gene can be on completely different paths depending on what’s actually broken. A missense mutation (one letter changed) might be fixable with base editing. A deletion (a whole section missing) needs a different plan entirely. The type of break determines which therapies even apply. That’s why genetic testing isn’t optional – it’s the first step. And why “gene therapy for USH2A” isn’t one conversation. It’s a dozen different conversations.

“Has anyone heard of DMSO for RP?”

Adriana H. (Blue Book) – son, 21, USH2A

The only real study I found was 123 patients over 7 years in the 1980s. It showed no benefit. No eye doctors recommend it. This is exactly why I wrote this essay – there’s so much junk floating around out there, and when nobody’s explaining what’s real, people reach for whatever they can find. The treatments in the pipeline are real science with real data. DMSO is not one of them.

“Can photoreceptors recover after surgery?”

Tanya N. (Russia) – USH2A

In a healthy eye, some recovery is possible after surgery because the cells were stressed, not dead. In an Usher or RP eye, the photoreceptors are already dying from the gene. Surgery can help with swelling or other complications, but it can’t grow new cells. The decline is the disease. Her doctor should have explained the difference – and didn’t. That pattern came up over and over in the questions I received.

“Can RP/USH be non-inherited? Did it start with me?”

Brian V. (Blue Book) – USH2A

Almost certainly inherited – and this isn’t just USH2A. Almost every gene that causes RP or Usher syndrome follows the same pattern: autosomal recessive. You need two broken copies, one from each parent. Spontaneous (de novo) mutations are extremely rare across all of them. The math is the same for every recessive gene: carriers – people with one broken copy – have no symptoms and no idea they’re carrying it. For USH2A alone, that’s roughly 1 in 70 to 150 people. Two carriers meet, and each child has a 25% chance. These genes are ancient – versions of them exist in fish, frogs, and every vertebrate with a spine. The mutations have been quietly passed through human families for thousands of years. It didn’t start with you. You’re just the one who got two copies.

“Can my son wear contact lenses? His doctor says no.”

Marzena G. (Poland) – son Kacper, 17, USH2A, “large astigmatism”

Contacts are safe for RP. The retina issue has nothing to do with what sits on your cornea. But “large astigmatism” at 17 is a red flag for something else: keratoconus – a condition where the cornea thins and bulges. Peak onset is around age 15. Research shows 9-17% of teens diagnosed with “astigmatism” actually have early keratoconus that nobody checked for. The fix is a corneal topography scan – takes five minutes. If it’s KC, rigid gas permeable lenses or scleral lenses can correct it. If it’s not, regular contacts are fine. Either way, the answer isn’t “no contacts.” The answer is “check the cornea first.”

“Why does the haze in my vision get worse when I wear my reading glasses?”

Brian V. (Blue Book) – USH2A

This might be another keratoconus sign. Glasses sit about 12mm from your eye, and at that distance they amplify any irregularity in the cornea. If the cornea is warped even slightly, glasses make it worse. Hard contact lenses sit directly on the eye and bypass the corneal surface entirely – that’s why some people see better with contacts than glasses. If the haze is worse with glasses, get a corneal topography scan.

“Do the different USH types map to the different RP types?”

Christine N. (Canada) – recessive RP + undefined hearing loss

No. All three Usher types (1, 2, 3) are autosomal recessive – you need two broken copies. The old RP classification (dominant, recessive, X-linked) applies to non-syndromic RP. Some genes, like USH2A, can cause either Usher syndrome or RP alone, depending on which mutations you have. A genetic test could connect your RP and hearing loss – and might open doors to trials you don’t know about.

“Should we act now or wait for something better?”

Multiple parents – Marzena G. (Poland), Anna R. (Czech Republic), Victoria L. (New York)

This is the hardest question in the essay and nobody can give you a universal answer. The tension: waiting for a better therapy might mean losing the cells that therapy needs. Acting now might close the door on something more effective coming later. Where your child is in the progression changes everything. What I can say based on my research: a neuroprotective pill that preserves cells without surgery and without triggering immune responses that could block future gene therapy – based on what we know today, that’s likely the lowest-risk first step. It buys time without closing doors. But every case is different. That’s why the framework I describe in this essay matters more than any specific answer.

The Pattern

These questions came from ten countries. Parents, patients, researchers. All asking variations of the same thing: what’s out there, and why didn’t anyone tell me?

That’s the gap this essay is about. Not one country. Not one healthcare system. Everywhere.

What Changed in This Revision

This essay is a living document. Below is what was updated, added, or corrected in Revision C, with sources.

Date Change Source Feb 17, 2026 NPI-001: Added that primary endpoint did not reach statistical significance; >50% photoreceptor preservation was secondary measure Nacuity Phase 1/2 results, Sep 2025 Feb 17, 2026 NAC Attack: Updated to 485 patients across 31 sites (was ~438/30) Johns Hopkins / NEI protocol, Nov 2025 Feb 17, 2026 OCU-400: FDA granted Expanded Access Program (pre-approval access) Ocugen press release, 2025 Feb 17, 2026 SPVN06 (SparingVision): Dosing COMPLETE in PRODYGY trial; pivotal trial planned 2027 SparingVision press release, Feb 9, 2026 Feb 17, 2026 SPVN20/NYRVANA: NEW entry – cone reactivation therapy, first patient Oct 2025 SparingVision / FFB, Oct 2025 Feb 17, 2026 Cone reactivation added to treatment menu (now 7 approaches, was 6) SparingVision NYRVANA trial Feb 17, 2026 OpCT-001: Orphan Drug Designation added (Jan 22, 2026) Bayer/BlueRock press release Feb 17, 2026 ZM-02: 52-week data showing color perception recovery; FDA IND cleared for US Zhongmou Therapeutics, ARVO/eyewire Feb 17, 2026 KIO-301: Phase 2 ABACUS-2 enrolling; $400M+ Senju partnership Kiora Q3 2025 report Feb 17, 2026 HORA-PDE6b: Company renamed from Coave to eyeDNA; therapy renamed eyeDNA Therapeutics Feb 17, 2026 Ultevursen: Added 16,000 exon 13 patient estimate Sepul Bio / FFB Feb 17, 2026 EDIT-102: Confirmed still dead – no partner, no IND, no timeline Editas pipeline review Feb 17, 2026 Laru-zova: Fully enrolled, positive 9-month interim data from DAWN trial Beacon Therapeutics, EURETINA 2025 Feb 17, 2026 DB-OTO: NEJM published – 11/12 improved, 3 achieved normal hearing NEJM, 2025 Feb 17, 2026 Community Q&A section added – 10 questions from 10 countries USH Blue Book, Facebook, LinkedIn Feb 17, 2026 Gene-independent trial count updated to 18+ (was 15+) FFB pipeline, verified Feb 17, 2026 RUSH2A 4-year data now publicly available FFB / Jaeb Center, Nov 2025

All data verified against ClinicalTrials.gov, FFB pipeline, company press releases, and published research as of February 17, 2026.

This revision was shaped by conversations on the USH Blue Book, Facebook, and LinkedIn. Their questions made it better.

Mark Hubers has Usher syndrome Type 2A and has been losing his vision progressively since his twenties. He was diagnosed at 43 and is now 57. He writes about the experience of living with dual sensory loss – and increasingly, about the gap between what science promises and what patients actually receive.

Important: This essay reflects one patient’s research as of February 2026. It is not medical advice. The treatment landscape changes rapidly – trials open, close, succeed, and fail. Verify all information at ClinicalTrials.gov and with your healthcare providers before making any treatment decisions. Links to key resources:

ClinicalTrials.gov:
--> LINK: https://clinicaltrials.gov

Foundation Fighting Blindness Clinical Trial Pipeline:
--> LINK: https://www.fightingblindness.org/clinical-trial-pipeline

USH Coalition Clinical Trials:
--> LINK: https://www.usher-syndrome.org/research/clinical-trials.html

My Retina Tracker (free genetic registry):
--> LINK: https://www.myretinatracker.org

RUSH2A Natural History Data (4-year USH2A dataset, public access):
--> LINK: https://public.jaeb.org/ffb/view/RUSH2A

I’m posting this to help others understand—not just what it’s like for me, but for anyone living with Usher Syndrome. If you’re a friend, a family member, or someone trying to support someone with USH, I hope this gives you insight into how and why it works the way it does.

What It’s Like Living with Usher Syndrome

I’m deaf—but not deaf. Blind—but not blind. I live with Usher Syndrome, and I’ve spent years studying how it affects me—not just physically, but cognitively and emotionally. This isn’t a guide on how I adapt. It’s a window into how it feels to live inside this shrinking sensory map.

What Normal Vision Actually Is—and Why Pictures Fail

Before I describe what I see, you need to understand what YOU see.

Most people think they see everything around them. But they don’t. Your field of view is about 120 degrees forward, and beyond that—there’s nothing. Not black. Not blur. Just absence. And yet, you never notice it. Your brain fills in the blanks so seamlessly that you think you’re seeing a full panorama.

Everyone has this void. You don’t see behind your head, and you don’t see the edges of your own eyes. But your brain fills in the blanks. You know what’s around you because you’ve seen it before. You’ve built a model.

That’s why it’s so hard to show what vision loss feels like. Most simulations use a small circle of sight surrounded by black. But that’s wrong. I don’t see black around my vision. I see nothing. And you do too—just not consciously.

You can’t make a picture show “void.” You can only fake it. And that’s part of the challenge in helping others understand what it’s like to live with USH2.

Vision at 8 Degrees and Shrinking

With USH, that brain model starts to collapse.

I’m now down to around 8 degrees or less. That’s so small I can’t see a full face unless it’s perfectly centered. Seeing with 8% of your visual field isn’t just narrow—it’s unpredictable.

In familiar places, your brain fills in blanks with memory and habit. I feel like I see more than I do—but it’s just memory doing the work.

In new environments, that fill-in function collapses. Your usable field shrinks even more, and you’re left scanning like a machine—grid by grid—hoping to catch something before it slips past the edge. I see less. I feel lost. There’s no model to lean on.

It takes much longer to study new areas. I’ve learned to scan and give my brain time to build a model—but that model is fragile.

The Void and the Washout

The parts of vision that are dying off don’t vanish cleanly—they fray. They wash out like static, scattered with random dead cells.

The areas I can’t see aren’t dark—they’re just gone. No color, no blur, no edge. It’s not like closing your eyes. It’s like those parts of the world never existed.

Cognitive Overload and Stress Collapse

As peripheral vision shrinks—slowly, almost imperceptibly—our brains work overtime to keep up. At around 20% field, you start to feel it. The brain doesn’t get enough data to build the world around you. It starts guessing. It starts failing.

Stress makes it worse. When the brain is overloaded, it stops filling in blanks. It stops compensating. Your world shrinks even more. You lose the ability to model your surroundings, and basic tasks—like finding a seat or recognizing a friend—become monumental.

I rarely feel stressed at work. There, I control the environment. But in social settings—bars, restaurants, parties—it’s chaos. And chaos is the enemy of accessibility.

Deaf, But Not Deaf

Without my hearing aids, I hear nothing. With them, I hear enough—sometimes.

In quiet places, I can catch about 75% of what’s said. That’s a gift.

In noisy environments—background noise, multiple voices, music, clinking glasses—that drops fast. Ten percent comprehension, maybe less.

People don’t know. They see me miss a word, pause too long, or respond offbeat—and they assume I’m slow. Not smart. Not engaged.

But I am. I’m just decoding chaos.

Motion, Blur, and the Loss of Rods

Rods are the cells that detect light and motion. They’re fast, sensitive, and work in low light. Cones, on the other hand, see color—but they’re slow and need strong light to function.

Most of my rods are gone. That means:

• I can’t track motion well. A ball flying through the air? Nearly invisible.

• Someone walking into view? Feels like they appeared out of nowhere.

• Even sign language is hard now. I can’t follow fast hand movements. I have to look up and down—lips, hands, lips, hands—and if they move too quickly, it’s just a blur. I miss the message. I miss the moment.

The Bright Light Paradox

Just like you, I’ve noticed something strange: bright lights don’t help—they hurt.

In dark areas or even on a sunny day, a bare bulb or uncovered light source can wash out everything else. You’d think, “If I can’t see well, shouldn’t more light help?” But it doesn’t.

As we lose rods—the cells that handle low light and motion—our cones take over. But cones aren’t built for harsh contrast. They’re slow, they need strong light, and they don’t handle glare well.

So instead of clarity, we get pain. Instead of detail, we get distortion.

And it gets worse over time. The more vision we lose, the more these lights dominate the field. They don’t illuminate—they overwhelm.

Crowds, Faces, and Social Spaces

Most meetups happen in the worst possible environments for someone with USH2:

• New location → unfamiliar layout (brain can’t fill in blanks)

• Dim lighting → cones struggle, rods are gone

• Loud background → hearing clarity vanishes (75% → 10%)

• Crowded space → constant scanning, no peripheral help

Reading someone’s face requires full-field vision. But with 8 degrees or less, I might only catch a mouth or an eye—never both. Microexpressions? Gone. Subtle cues? Missed. I rely on tone, context, and educated guesses. And that’s risky.

Suggesting a quieter, more controlled space—like my home—makes sense. But socially? It’s loaded. People hear “my place” and think it’s weird, forward, or inappropriate.

What I mean is: I need clarity to connect.

What they hear is: You’re crazy.

What Family and Friends Ask

People often ask, “What does your kid see with USH?” or “How do you get around?”

What they’re really asking is: What does it feel like to live inside that view?

It’s not just about what’s missing—it’s about how the brain, the body, and the emotions respond to that missingness.

• How long it takes to recover from a noisy dinner.

• How hard it is to find something you dropped on the floor.

• How exhausting it is to navigate a new space when your brain has no model to work from.

The Work Environment I Need

At work, I control the environment:
- Familiar layout (brain fills in blanks)
- Quiet space (75% hearing comprehension)
- Known lighting (no harsh glare)
- Predictable routine (no cognitive collapse)

This is why I rarely feel stressed at work. And it’s why I’m productive there.

Office environments are the opposite:
- New spaces (cognitive collapse)
- Fluorescent lighting (visual washout)
- Background noise (10% comprehension)
- Interruptions (constant scanning stress)

Remote work isn’t a preference. It’s survival.

Thank You for Reading

This is just one perspective—but it’s real. And if it helps even one person see the world a little differently, it’s worth sharing.